

PSJ3

Exhibit 150

Campbell Alliance Group, Ltd.
REMS Management Support Project

1. Overview

variance views of the REMS project.

Additional schedules may be included in future submissions based on RPC member company feedback

2. Schedules

Summary by Vendor

Billing by Member

Cost by Member

Budget

PO Status

Forecast Changes

Member Allocations

Deposit Activity

CE Pre-Paid

CE Grant Summary by Grant

CE Grant Summary by Month

AR Aging

AP Aging

3. Definitions

Forecast

Budget

The Summary by Vendor page summarizes all costs by Vendor name and presents the full year forecast the budget.

The Summary by Vendor page summarizes all costs previously invoiced and estimated to be invoiced to each RPC Member company. The full year forecast is presented in this tab. Costs shown on a cash accounting basis.

The Summary by Vendor page summarizes all costs allocated to each RPC Member company. The full year forecast is presented in this tab. Costs shown on a cash accounting basis.

The Budget tab shows the budget by area of spend. The data presented is full year forecast for 2012 compared against the budget for 2012. Data is also presented by each project phase and for 2013 and 2014.

The PO Status tab details data on a PO issued by each RPC member company. PO issues are highlighted and presented in this tab.

The Forecast Changes tab shows the detail of the changes to the forecast and explanations for changes in billing for the current month on the Summary by Vendor tab from the prior month.

The Member Allocations tab presents the IMS market share data for each RPC member company. The market share data has been adjusted to sum to 100%. The market share data is used for the allocation of costs to be allocated based on market share per the RPC agreement.

The Deposit Activity tab shows the all activity related to RPC member company deposit invoicing per the agreement. Any deposit reallocations or changes are shown and highlighted in this tab.

The CE Pre-Paid tab is a reconciliation between the pre-paid invoiced by Campbell to the RPC committee and the actual costs invoiced to Campbell by the vendor. This pre-paid will be reconciled at year-end 2012.

The CE Grant Summary tab is a summary of grants approved, scheduled milestone payments and actual dates paid by Campbell to Polaris.

The CE Grant Summary tab is a detail of grant payments billed each month as it corresponds to the Summary by Vendor.

The AR Aging tab shows both a summary of receivables outstanding by member company and the details of the invoices making up the total receivables outstanding. The detailed invoice data can be accessed by expanding each members summary line.

The AP Aging tab shows outstanding vendor payables on Campbell Alliance's balance sheet. These payables will be paid timely in accordance with payment terms on executed contracts. Any past due payables will include commentary to explain its status.

The Forecast is composed of the actual year to date invoiced to Campbell Alliance from Vendors plus the forecasted invoices for the remainder of the year. The data is presented on a calendar year basis and on a cash accounting basis. The Forecast can change monthly

The budget is the Budget set at the beginning of the project for each vendor. The budget will not change without approval from the RPC committee

[illegible]

Development Phase

Total Development Phase Costs	3,085,092	822,000	1,144,262	274,000	2,240,262	554,143	7,495	283,191	844,830	3,085,092
-------------------------------	-----------	---------	-----------	---------	-----------	---------	-------	---------	---------	-----------

Allocation 11/1/12

Total Operations Phase Costs	94.54%	100.00%	5,315,685	337,157	4,062,948	-	4,400,105	156,202	242,839	328,076	727,117	5,127,222
------------------------------	--------	---------	-----------	---------	-----------	---	-----------	---------	---------	---------	---------	-----------

Total Development and Operations Costs	8,400,777	1,159,157	5,207,210	274,000	6,640,367	710,345	250,334	611,267	1,571,947	8,212,314
---	------------------	------------------	------------------	----------------	------------------	----------------	----------------	----------------	------------------	------------------

	47,586	46,566	357	-	46,923	662	-
--	--------	--------	-----	---	--------	-----	---

100.00%	12,857,208	1,258,781	2,598,586	324,223	4,181,590	3,705,887	0
---------	------------	-----------	-----------	---------	-----------	-----------	---

Billing by RPC Member													Allocation 3/31/13 FORECAST								
Prepayments		Allocation 7/7/12	Allocation 11/1/12	ACTUAL									Allocation 3/31/13	FORECAST	YTD (TBD)	JAN	FEB	MAR	Q1	APR	APR
Committee Member				YTD (OCT)	JUL	AUG	SEP	Q3 2012	OCT	NOV	DEC	Q4 2012	Y2012								
Actavis Group, I.f.		3.95%	0.00%	-	-	-	-	-	-	-	-	-	-	0.00%	-	-	-	-	-	-	
Endo Pharmaceuticals Inc.		8.80%	8.80%	-	-	-	-	-	-	-	-	-	-	5.74%	-	-	-	-	-	-	
Janssen Pharmaceuticals, Inc.		1.37%	1.37%	-	-	-	-	-	-	-	-	-	-	1.83%	-	-	-	-	-	-	
Mallinckrodt, Inc.		20.16%	20.16%	-	-	-	-	-	-	-	-	-	-	22.28%	-	-	-	-	-	-	
Mylan Technologies, Inc.		14.21%	14.21%	-	-	-	-	-	-	-	-	-	-	15.67%	-	-	-	-	-	-	
Noven Pharmaceuticals, Inc.		1.17%	1.17%	-	-	-	-	-	-	-	-	-	-	1.11%	-	-	-	-	-	-	
Pfizer, Inc.		1.04%	1.04%	-	-	-	-	-	-	-	-	-	-	0.89%	-	-	-	-	-	-	
Purdue Pharma, L.P.		25.75%	25.75%	-	-	-	-	-	-	-	-	-	-	25.36%	-	-	-	-	-	-	
Rhodes Pharmaceuticals L.P.		7.31%	7.31%	-	-	-	-	-	-	-	-	-	-	7.02%	-	-	-	-	-	-	
Roxane Laboratories, Inc.		9.47%	9.47%	-	-	-	-	-	-	-	-	-	-	9.84%	-	-	-	-	-	-	
Sandoz Inc.		1.22%	1.22%	-	-	-	-	-	-	-	-	-	-	1.29%	-	-	-	-	-	-	
The PharmaNetwork, LLC		0.08%	0.08%	-	-	-	-	-	-	-	-	-	-	0.00%	-	-	-	-	-	-	
VistaPharm, Inc.		0.01%	0.01%	-	-	-	-	-	-	-	-	-	-	0.00%	-	-	-	-	-	-	
Watson Laboratories, Inc.		5.46%	9.41%	-	-	-	-	-	-	-	-	-	-	6.50%	-	-	-	-	-	-	
Impax Laboratories, Inc.		0.00%	0.00%	-	-	-	-	-	-	-	-	-	-	0.00%	-	-	-	-	-	-	
Apotex		0.00%	0.00%	-	-	-	-	-	-	-	-	-	-	0.00%	-	-	-	-	-	-	
Par Pharmaceuticals		0.00%	0.00%	-	-	-	-	-	-	-	-	-	-	2.45%	-	-	-	-	-	-	
Ranbaxy		0.00%	0.00%	-	-	-	-	-	-	-	-	-	-	0.01%	-	-	-	-	-	-	
Upsher-Smith		0.00%	0.00%	-	-	-	-	-	-	-	-	-	-	0.00%	-	-	-	-	-	-	
Zogenix		0.00%	0.00%	-	-	-	-	-	-	-	-	-	-	0.00%	-	-	-	-	-	-	
Nesher		0.00%	0.00%	-	-	-	-	-	-	-	-	-	-	0.00%	-	-	-	-	-	-	
Total Operations Phase Costs		100.00%	100.00%	-	-	-	-	-	-	-	-	-	-	100.00%	-	-	-	-	-	-	

Deposits													Allocation 3/31/13 ACTUAL									
Committee Member		Allocation 7/7/12	Allocation 11/1/12	YTD (DEC)	JUL	AUG	SEP	Q3 2012	OCT	NOV	DEC	Q4 2012	Y2012	Allocation 3/31/13	ACTUAL	YTD (NOV)	JAN	FEB	MAR	Q1	APR Cost and Q1, '13 True-up	APR 2012 True-up
Actavis Group, I.f.		3.95%	0.00%	-	243,841	-	(7,253)	236,588	-	-	(236,588)	(236,588)	-	0.00%	-	-	-	-	-	-	-	-
Endo Pharmaceuticals Inc.		8.80%	8.80%	464,270	471,523	-	(7,253)	464,270	-	-	-	-	464,270	5.74%	(202,212)	(2,987)	-	-	(2,987)	-	(199,225)	(199,225)
Janssen Pharmaceuticals, Inc.		1.37%	1.37%	115,220	122,474	-	(7,253)	115,220	-	-	-	-	115,220	1.83%	(21,563)	(2,987)	-	-	(2,987)	-	(18,576)	(18,576)
Mallinckrodt, Inc.		20.16%	20.16%	998,663	1,005,917	-	(7,253)	998,663	-	-	-	-	998,663	22.28%	18,267	(2,987)	-	-	(2,987)	-	21,253	21,253
Mylan Technologies, Inc.		14.21%	14.21%	718,765	726,019	-	(7,253)	718,765	-	-	-	-	718,765	15.67%	(3,504)	(2,987)	-	-	(2,987)	-	(517)	(517)
Noven Pharmaceuticals, Inc.		1.17%	1.17%	105,812	113,065	-	(7,253)	105,812	-	-	-	-	105,812	1.11%	(55,190)	(2,987)	-	-	(2,987)	-	(52,203)	(52,203)
Pfizer, Inc.		1.04%	1.04%	99,697	106,950	-	(7,253)	99,697	-	-	-	-	99,697	0.89%	(59,208)	(2,987)	-	-	(2,987)	-	(56,221)	(56,221)
Purdue Pharma, L.P.		25.75%	25.75%	1,261,156	1,268,409	-	(7,253)	1,261,156	-	-	-	-	1,261,156	25.36%	(103,676)	(2,987)	-	-	(2,987)	-	(100,689)	(100,689)
Rhodes Pharmaceuticals L.P.		7.31%	7.31%	394,178	401,431	-	(7,253)	394,178	-	-	-	-	394,178	7.02%	(73,750)	(2,987)	-	-	(2,987)	-	(70,764)	(70,764)
Roxane Laboratories, Inc.		9.47%	9.47%	495,788	503,041	-	(7,253)	495,788	-	-	-	-	495,788	9.84%	(46,536)	(2,987)	-	-	(2,987)	-	(43,549)	(43,549)
Sandoz Inc.		1.22%	1.22%	108,164	115,417	-	(7,253)	108,164	-	-	-	-	108,164	1.29%	(49,237)	(2,987)	-	-	(2,987)	-	(46,250)	(46,250)
The PharmaNetwork, LLC		0.08%	0.08%	54,537	61,790	-	(7,253)	54,537	-	-	-	-	54,537	0.00%	(54,537)	(2,987)	-	-	(2,987)	-	(51,550)	(51,550)
VistaPharm, Inc.		0.01%	0.01%	51,244	58,497	-	(7,253)	51,244	-	-	-	-	51,244	0.00%	(51,244)	(2,987)	-	-	(2,987)	-	(48,257)	(48,257)
Actavis Group, I.f. (Formerly Watson)		-	9.41%	493,435	314,874	-	(7,253)	307,620.81	-	185,815	185,815	185,815	493,435	6.50%	(196,738)	(2,987)	-	-	(2,987)	-	(193,751)	(193,751)
Impax Laboratories, Inc.		0.00%	0.00%	50,773	-	-	-	50,773	-	-	-	-	50,773	0.00%	(50,773)	(2,987)	-	-	(2,987)	-	(47,787)	(47,787)
Apotex		0.00%	0.00%	50,773	-	-	-	50,773	-	-	-	-	50,773	0.00%	(50,773)	(2,987)	-	-	(2,987)	-	(47,787)	(47,787)
Par Pharmaceuticals		0.00%	0.00%	50,773	-	-	-	-	-	50,773	50,773	50,773	50,773	2.45%	60,853	(2,987)	-	-	(2,987)	-	63,840	63,840
Ranbaxy		0.00%	0.00%	-	-	-	-	-	-	-	-	-	-	0.01%	439	47,787	-	-	47,787	-	(47,348)	(47,348)
Upsher-Smith		0.00%	0.00%	-	-	-	-	-	-	-	-	-	-	0.00%	-	-	-	-	-	-	-	-
Zogenix		0.00%	0.00%	-	-	-	-	-	-	-	-	-	-	0.00%	-	-	-	-	-	-	-	-
Nesher		0.00%	0.00%	-	-	-	-	-	-	-	-	-	-	0.00%	-	-	-	-	-	-	-	-
Total Deposits Costs		94.54%	100.00%	5,513,247	5,513,247	-	0	5,513,247	-	-	(0)	(0)	5,513,247	100.00%	(939,380)	(0)	-	-	(0)	-	-	(939,380)

Total													Allocation 3/31/13 ACTUAL									
Committee Member		Allocation 7/7/12	Allocation 11/1/12	YTD (DEC)	JUL	AUG	SEP	Q3 2012	OCT	NOV	DEC	Q4 2012	Y2012	Allocation 3/31/13	ACTUAL	YTD (NOV)	JAN	FEB	MAR	Q1	APR Cost and Q1, '13 True-up	APR 2012 True-up
Actavis Group, I.f.		3.95%	0.00%	-	243,841	-	(7,253)	236,588	-	-	(236,588)	(236,588)	-	0.00%	-	-	-	-	-	-	-	-
Endo Pharmaceuticals Inc.		8.80%	8.80%	1,092,163	557,546	432,797	380	990,722	43,935	21,829	35,677	101,441	1,092,163	5.74%	362,508	99,919	228,596	28,389	356,904	85,254	(355,265)	(355,265)
Janssen Pharmaceuticals, Inc.		1.37%	1.37%	362,407	183,462	131,115	380	314,956	32,336	3,798	11,317	47,451	362,407	1.83%	220,632	6,452	35,645	4,384	46,481	87,269	5,292	5,292
Mallinckrodt, Inc.		20.16%	20.16%	2,209,416	1,130,267	894,670	380	2,025,317	61,692	49,435	72,973	184,100	2,209,416	22.28%	2,974,488	243,017	524,002	64,608	831,627	914,265	131,992	131,992
Mylan Technologies, Inc.		14.21%	14.21%	1,624,235	830,294	652,755	380	1,483,429	52,391	34,976	53,439	140,806	1,624,235	15.67%	2,069,439	168,067	369,278	45,700	583,045	641,916	75,965	75,965
Noven Pharmaceuticals, Inc.		1.17%	1.17%	342,737	173,378	122,983	380	296,741	32,024	3,312	10,661	45,996	342,737	1.11%	67,353	3,933	30,445	3,744	38,121	38,567	(55,257)	(55,257)
Pfizer, Inc.		1.04%	1.04%	329,952	166,824	117,698	380	284,902	31,821	2,996	10,234	45,050	329,952	0.89%	29,813	2,295	27,064	3,328	32,687	26,499	(64,012)	(64,012)
Purdue Pharma, L.P.		25.75%	25.75%	2,758,209	1,411,586	1,121,542	380	2,533,507	70,414	62,995	91,292	224,701	2,758,209	25.36%	3,123,934	313,306	669,104	82,594	1,065,005	923,786	(118,055)	(118,055)
Rhodes Pharmaceuticals L.P.		7.31%	7.31%	945,621	482,426	372,216	380	855,022	41,606	18,208	30,786	90,600	945,621	7.02%	797,151	81,150	189,850	23,359	294,359	248,356	(84,660)	(84,660)
Roxane Laboratories, Inc.		9.47%	9.47%	1,158,057	591,324	460,037	380	1,051,741	44,982	23,457	37,877	106,316	1,158,057	9.84%	1,221,688	108,359	246,018	30,796	385,173	380,582	(23,271)	(23,271)
Sandoz Inc.		1.22%	1.22%	347,655	175,899	125,016	380	301,295	32,102	3,433	10,825	46,360	347,655	1.29%	103,205	4,563	31,745	3,904	40,211	50,823	(42,521)	(42,521)
The PharmaNetwork, LLC		0.08%	0.08%	235,536	118,425	78,666	380	197,471	30,320	663	7,082	38,065	235,536	0.00%	(75,668)	(9,798)	2,100	387	(7,310)	(3,307)	(55,655)	(55,655)
VistaPharm, Inc.		0.01%	0.01%	128,651	114,896	75,819	380	191,095	30,211	493	6,852	37,556	128,651	0.00%	(68,915)	(10,679)	280	32	(10,367)	(381)	(48,770)	(48,770)
Actavis Group, I.f. (Formerly Watson)		-	9.41%	1,327,220	459,354	533,418	8,012	1,000,784	75,099	23,803	227,534	326,436	1,327,220	6.50%	594,268	110,316	244,738	31,554	386,608	119,207	(226,703)	(226,703)
Impax Laboratories, Inc.		0.00%	0.00%	227,668	-	55,842	134,343	190,185	30,195	468	6,819	37,483	227,668	0.00%	(67,406)	(10,805)	20	525	(10,260)	37	(47,787)	(47,787)
Apotex		0.00%	0.00%	227,668	-	-	134,343	134,343														

Billing By Member JAN-MS-02659095_Confidential.xlsx 7/30/2019

													Allocation 3/31/13	FORECAST	ACTUAL	FORECAST					
MAY	JUN	Q2		JUL	AUG	SEP	Q3	OCT	NOV	DEC	Q4		Y2013	YTD (TBD)	JAN	FEB	MAR	Q1	APR	APR	MAY
		-					-				-		-	0.00%				-			
		-					-				-		-	5.74%				-			
		-					-				-		-	1.83%				-			
		-					-				-		-	22.28%				-			
		-					-				-		-	15.67%				-			
		-					-				-		-	1.11%				-			
		-					-				-		-	0.89%				-			
		-					-				-		-	25.36%				-			
		-					-				-		-	7.02%				-			
		-					-				-		-	9.84%				-			
		-					-				-		-	1.29%				-			
		-					-				-		-	0.00%				-			
		-					-				-		-	0.00%				-			
		-					-				-		-	6.50%				-			
		-					-				-		-	0.00%				-			
		-					-				-		-	0.00%				-			
		-					-				-		-	2.45%				-			
		-					-				-		-	0.01%				-			
		-					-				-		-	0.00%				-			
		-					-				-		-	0.00%				-			
		-					-				-		-	0.00%				-			
		-					-				-		-	100.00%				-			

													Allocation 3/31/14	ACTUAL							
MAY	JUN	Q2		JUL	AUG	SEP	Q3	OCT	NOV	DEC	Q4		Y2013	YTD (NOV)	JAN	FEB	MAR	Q1 2014	APR and Q1 True-up	2013 True-up	MAY
-	-	-		-	-	-	-	-	-	-	-		-	0.00%	-			-			
-	-	(199,225)		-	-	-	-	-	-	-	-		(202,212)	3.82%	(85,612)			-		(85,612)	
-	-	(18,576)		-	-	-	-	-	-	-	-		(21,563)	1.77%	(11,957)			-		(11,957)	
-	-	21,253		-	-	-	-	-	-	-	-		18,267	22.66%	28,386			-		28,386	
-	-	(517)		-	-	-	-	-	-	-	-		(3,504)	16.28%	36,005			-		36,005	
-	-	(52,203)		-	-	-	-	-	-	-	-		(55,190)	0.14%	(43,973)			-		(43,973)	
-	-	(56,221)		-	-	-	-	-	-	-	-		(59,208)	0.70%	(8,044)			-		(8,044)	
-	-	(100,689)		-	-	-	-	-	-	-	-		(103,676)	24.67%	(19,288)			-		(19,288)	
-	-	(70,764)		-	-	-	-	-	-	-	-		(73,750)	10.49%	163,669			-		163,669	
-	-	(43,549)		-	-	-	-	-	-	-	-		(46,536)	8.31%	(65,953)			-		(65,953)	
-	-	(46,250)		-	-	-	-	-	-	-	-		(49,237)	0.55%	(33,478)			-		(33,478)	
-	-	(51,550)		-	-	-	-	-	-	-	-		(54,537)	0.62%	28,464			-		28,464	
-	-	(48,257)		-	-	-	-	-	-	-	-		(51,244)	0.00%	-			-		-	
-	-	(193,751)		-	-	-	-	-	-	-	-		(196,738)	6.44%	271			-		271	
-	-	(47,787)		-	-	-	-	-	-	-	-		(50,773)	0.00%	-			-		-	
-	-	(47,787)		-	-	-	-	-	-	-	-		(50,773)	1.45%	66,807			-		66,807	
-	-	63,840		-	-	-	-	-	-	-	-		60,853	2.09%	(15,119)			-		(15,119)	
-	-	(47,348)		-	-	-	-	-	-	-	-		439	0.00%	(439)			-		(439)	
-	-	-		-	-	-	-	-	-	-	-		-	0.00%	-			-		-	
-	-	-		-	-	-	-	-	-	-	-		-	0.00%	-			-		-	
-	-	-		-	-	-	-	-	-	-	-		-	0.00%	-			-		-	
-	-	(939,380)		-	-	-	-	-	-	-	-		(939,380)	100.00%	39,742			-		39,742	

													Allocation 3/31/14	ACTUAL								
MAY	JUN	Q2		JUL	AUG	SEP	Q3	OCT	NOV	DEC	Q4		Y2013	YTD (NOV)	JAN	FEB	MAR	Q1 2014	APR and Q1 True-up	2013 True-up	MAY	
-	-	-		-	-	-	-	-	-	-	-		-	0.00%	-			-		-		
27,489	20,399	(222,122)		128,446	54,885	16,896	200,227	15,122	12,377	36,378	63,877		398,886	3.82%	527,454	78,666	187,455	23,112	289,234	(17,409)	(175,977)	167,911
8,776	6,512	107,849		34,608	17,521	5,394	57,523	4,828	3,951	5,890	14,668		226,521	1.77%	284,563	25,113	59,842	7,378	92,333	33,532	(43,126)	77,749
106,674	79,158	1,232,089		525,508	212,984	65,566	804,058	58,683	48,031	165,383	272,097		3,139,871	22.66%	4,141,543	305,269	727,430	89,689	1,122,389	487,982	(27,615)	994,750
75,030	55,676	848,587		366,831	149,803	46,116	562,750	41,275	33,783	113,829	188,886		2,183,267	16.28%	3,020,565	214,712	511,640	63,083	789,436	367,933	25,522	714,925
5,573	3,940	(7,177)		17,231	10,602	3,264	31,097	2,921	2,391	244	5,556		67,597	0.14%	(149,677)	15,196	36,211	4,465	55,871	(45,628)	(176,185)	6,328
4,247	3,152	(30,114)		11,901	8,480	2,610	22,991	2,336	1,912	(1,488)	2,761		28,326	0.70%	105,471	12,154	28,963	3,571	44,688	5,296	(23,876)	30,875
121,418	90,099	1,017,247		599,438	242,421	74,628	916,486	70,527	54,669	189,402	314,598		3,313,336	24.67%	4,442,549	347,461	827,968	102,085	1,277,514	475,937	(97,836)	1,083,133
33,612	24,942	222,250		159,148	67,110	20,659	246,917	18,491	15,134	46,353	79,978		843,504	10.49%	2,557,681	96,188	229,208	28,260	353,656	392,122	627,753	460,679
47,126	34,970	439,407		226,910	94,091	28,965	349,966	25,924	21,219	68,369	115,512		1,290,057	8.31%	1,263,262	134,860	321,359	39,622	495,841	94,654	(266,659)	364,758
6,181	4,587	19,070		21,599	12,342	3,799	37,740	3,400	2,783	1,663	7,847		104,868	0.55%	(37,113)	17,689	42,152	5,197	65,038	(25,832)	(142,420)	24,218
-	-	(58,962)		(9,396)	-	-	(9,396)	-	-	(8,407)	(8,407)		(84,075)	0.62%	220,179	-	-	-	-	43,851	106,701	27,087
-	-	(49,151)		(9,396)	-	-	(9,396)	-	-	(8,407)	(8,407)		(77,322)	0.00%	974	-	-	-	-	974	-	-
31,123	23,095	(53,277)		146,667	62,140	19,129	227,936	18,988	14,013	42,298	75,299		636,566	6.44%	1,218,169	89,065	212,234	26,168	327,467	130,032	30,801	282,604
-	-	(47,750)		(9,396)	-	-	(9,396)	-	-	(8,407)	(8,407)		(75,814)	0.00%	-	-	-	-	-	-	-	-
-	-	(47,750)		(9,396)	-	-	(9,396)	-	-	(8,407)	(8,407)		(76,339)	1.45%	522,941	-	-	-	-	102,920	256,605	63,575
11,709	8,689	277,704		49,319	23,379	7,197	79,895	6,441	5,272	10,669	22,383		369,852	2.09%	331,236	33,509	79,848	9,845	123,202	25,473	(53,505)	91,838
46	34	(46,472)		(9,165)	92	28	(9,045)	25	21	(8,332)	(8,286)		153,341	0.00%	(1,749)	132	314	39	485	(484)	(1,750)	-
-	-	-		159,736	-	263	159,999	-	-	(8,407)	(8,407)		151,592	0.00%	334	-	-	-	-	-	334	-
-	-	-		-	-	-	-	-	-	151,329	151,329		151,329	0.00%	4,550	-	-	3,850	3,850	-	-	-
-	-	-		-	-	-	-	-	-	151,329	151,329		151,329	0.00%	-	-	-	-	-	-	-	-
-	-	-		-	-	-	-	-	-	-	-		-	0.00%	-	-	-	-	-	-	-	-
479,005	355,252	3,601,426		2,400,592	955,849	294,514	3,650,954	268,962	215,558	931,279	1,415,799		12,896,692									

ACTUAL										
JUN	Q2	JUL	AUG	SEP	Q3	OCT	NOV	DEC	Q4	Y2014
-	-	-	-	-	-	-	-	-	-	-
73,303	133,440	32,945	13,679	9,028	55,551	76,561	58,179	28,498	163,239	641,564
33,942	114,054	17,227	6,334	4,180	27,741	35,451	26,939	13,196	75,586	309,715
434,266	1,860,996	195,174	81,037	55,320	331,530	453,571	344,669	168,830	967,070	4,281,986
312,106	1,384,481	140,271	58,241	38,438	236,950	325,981	247,713	121,338	695,031	3,105,897
2,762	(168,750)	1,241	515	340	2,097	2,885	2,192	1,074	6,151	(104,630)
13,479	33,818	6,058	2,515	1,660	10,233	14,078	10,698	5,240	30,016	118,755
472,850	1,953,372	212,515	88,237	58,234	358,986	493,871	378,093	183,830	1,055,794	4,645,666
201,113	1,517,998	90,387	37,529	24,768	152,684	210,053	159,620	78,187	447,860	2,472,198
159,238	417,943	71,567	29,715	21,449	122,730	166,317	126,384	61,907	354,608	1,391,121
10,573	(99,984)	4,752	1,973	1,302	8,027	11,043	12,241	4,110	27,394	475
11,825	161,000	5,315	2,207	1,456	8,978	12,351	9,385	4,597	26,334	196,312
-	974	-	-	-	-	-	-	-	-	974
123,373	566,539	58,900	23,022	15,194	97,116	128,857	97,919	47,964	274,740	1,265,862
-	-	-	-	-	-	-	-	-	-	-
27,754	384,047	12,474	5,179	3,418	21,071	28,988	22,028	10,790	61,806	466,924
40,093	119,018	18,019	7,482	4,938	30,438	41,875	31,821	15,587	89,283	361,941
-	(1,795)	-	-	-	-	-	-	-	-	(1,310)
-	334	-	-	-	-	-	-	-	-	334
-	334	-	-	-	-	-	700	-	700	4,550
-	-	-	-	-	-	-	-	-	-	-
1,916,678	8,377,486	866,845	357,663	239,725	1,464,233	2,001,883	1,528,582	745,147	4,275,613	19,158,334
1,916,678	8,377,486	866,845	357,663	239,725	1,464,233	2,001,883	1,528,582	745,147	4,275,613	19,158,334

ACTUAL											
JUN	Q2	JUL	AUG	SEP	Q3	OCT	NOV	DEC	Q4	Y2014	
73,303	47,828	32,945	13,679	9,028	55,651	76,561	58,179	20,931	155,672	548,385	
33,942	102,098	17,227	6,334	4,180	27,741	35,451	26,939	5,629	68,019	290,192	
434,266	1,889,383	195,174	81,037	55,320	331,530	453,571	344,669	161,263	959,504	4,302,806	
312,106	1,420,486	140,271	58,241	38,438	236,950	325,981	247,713	113,771	687,465	3,134,336	
2,762	(212,723)	1,241	515	340	2,097	2,885	2,192	(6,493)	(1,415)	(156,169)	
13,479	25,774	6,058	2,515	1,660	10,233	14,078	10,698	(2,326)	22,450	103,145	
472,850	1,934,085	212,515	88,237	58,234	358,986	493,871	378,093	176,264	1,048,228	4,618,812	
201,113	1,681,667	90,387	37,529	24,768	152,684	210,053	159,620	70,620	440,293	2,628,301	
159,238	351,990	71,567	29,715	21,449	122,730	166,317	126,384	54,340	347,041	1,317,602	
10,573	(133,462)	4,752	1,973	1,302	8,027	11,043	12,241	(3,456)	19,828	(40,569)	
11,825	189,465	5,315	2,207	1,456	8,978	12,351	9,385	(2,969)	18,767	217,210	
-	974	-	-	-	-	-	-	(7,566)	(7,566)	(6,593)	
123,373	566,810	58,900	23,022	15,194	97,116	128,857	97,919	40,397	267,173	1,258,566	
-	-	-	-	-	-	-	-	(7,566)	(7,566)	(7,566)	
27,754	450,854	12,474	5,179	3,418	21,071	28,988	22,028	3,224	54,240	526,165	
40,093	103,899	18,019	7,482	4,938	30,438	41,875	31,821	8,020	81,717	339,256	
-	(2,234)	-	-	-	-	-	-	(7,566)	(7,566)	(9,316)	
-	334	-	-	-	-	-	-	(7,566)	(7,566)	(7,232)	
-	-	-	-	-	-	-	700	(7,566)	(6,866)	(3,016)	
-	-	-	-	-	-	-	-	143,763	143,763	143,763	

Phase 1 - Development																		
Subteam	Y2012			Y2013			Y2014			Y2015			Y2016			Y2017		
	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)
Technology	632,079	648,233	16,154	0	0	0	0	0	0	0	0	0	0	0	0	632,079	648,233	16,154
Patient	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CE	75,000	125,000	50,000	0	0	0	0	0	0	0	0	0	0	0	0	75,000	125,000	50,000
Metrics	67,429	200,000	132,571	0	0	0	0	0	0	0	0	0	0	0	0	67,429	200,000	132,571
Vendor	1,907,556	2,051,500	143,944	2,586	0	(2,586)	0	0	0	100,000	100,000	0	100,000	100,000	0	100,000	100,000	0
Prescriber	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Legal	REDACTED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED																	
Operations	75,285	37,500	(37,785)	0	0	0	0	0	0	0	0	0	0	0	0	75,285	37,500	(37,785)
Subtotal	3,085,093	3,287,233	202,140	47,586	-	(47,586)	-	-	-	100,000	100,000	-	100,000	100,000	-	100,000	100,000	-

Phase 2 - Operations																		
Subteam	Y2012			Y2013			Y2014			Y2015			Y2016			Y2017		
	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)	Forecast	Budget	Fav (Unfav)
Technology	245,019	1,482,598	1,237,579	768,770	1,109,402	340,632	520,216	470,120	(50,096)	518,223	503,288	(14,935)	447,137	447,137	0	456,171	456,171	0
Patient	26,074	825,000	798,926	8,984	232,820	223,836	9,567	86,594	77,027	13,036	13,563	527	14,277	14,277	0	14,991	14,991	-
CE	0	655,000	655,000	137,381	137,381	0	868,966	696,574	(172,392)	807,499	445,000	337,501	425,000	425,000	-	425,000	425,000	-
CE-Grants	3,500,000	10,000,000	6,500,000	9,030,772	12,754,619	3,723,847	12,416,533	10,668,596	(1,747,943)	9,000,485	8,929,509	(70,976)	9,615,289	9,615,289	-	10,000,000	10,000,000	-
Metrics	91,626	2,850,000	2,758,374	309,788	1,778,142	1,468,354	2,710,266	3,799,100	1,088,834	3,850,883	3,366,573	(484,310)	3,451,532	3,370,974	(80,558)	3,451,532	3,352,554	(98,978)
Vendor	375,453	435,500	60,047	2,296,381	2,540,496	244,115	1,984,191	2,098,000	113,809	2,021,511	1,998,000	(23,511)	1,998,000	1,998,000	0	1,998,000	1,998,000	0
Prescriber	889,047	889,047	0	888,082	1,080,000	191,918	114,800	130,000	15,200	178,000	178,000	-	130,000	130,000	-	130,000	130,000	-
Legal	REDACTED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED: PRIVILEGED																	
Operations	0	0	-	0	0	-	0	0	-	0	0	-	0	0	-	0	0	-
Quality Management	0	0	-	0	0	-	190,257	450,000	259,743	352,991	324,996	(27,995)	265,908	265,908	-	265,908	265,908	-
External Communications	0	0	-	0	0	-	103,540	0	(103,540)	3,557,396	3,346,000	(211,396)	1,082,000	1,082,000	0	1,082,000	1,082,000	0
Subtotal	5,127,221	17,137,145	12,009,925	13,637,158	19,632,860	5,995,702	19,158,335	18,578,978	(579,357)	19,995,023	19,284,929	(710,094)	17,609,143	17,528,585	(80,558)	18,003,602	17,904,624	(98,978)

Budget Changes Summary																		
	2012 DEV	2012 OPER	2013	2014	2015	2016	2017											
Original Budget	3,249,483	17,633,025	19,036,980	18,578,978	19,336,929	17,628,585	18,004,624											
Changes	37,750	-	-	-	-	-	-	Approved by RPC vote 7/13/12 for additional funding for GMS (Polaris) budget to enable GMS implementation to meet FDA CE deadline.										
	-	(595,880)	595,880	-	-	-	-	Approved by RPC vote 8/29/12 to move \$595,880 from 2012 to 2013 for DHCLP 2										
	-	-	-	-	48,000	-	-	Approved by RPC vote 12/10/14 to add \$48,000 CE Grantee Reimbursement to April, 2015										
Amended Total	3,287,233	17,037,145	19,632,860	18,578,978	19,384,929	17,628,585	18,004,624											
Variance	-	(100,000)	-	-	-	-	-											

REMS Changes to Forecast in Summary by Vendor Tab

February 28, 2015

						Net Effect - Fav (Unfav)			
Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017
Ashfield	Call Center	Jan to Dec 2014	January reflects \$18,095 covering January and February costs. Reduced fees when IVR implementation occurs in February. Reduced amount to start in March 2014. An additional adjustment to make is to incorporate the IVR setup fee. This will be \$13,710 for month of changeover in February. We then anticipate costs to drop to \$3,215 per month thereafter.	Line 25					
Polaris	Grant Management System / CE Portal Setup	Jan to Dec 2014	Moved \$86,000 from CE Portal Setup to Grant Management System line increasing each month by \$7,166	Line 26 and 28					
Polaris	CE Grants	Feb 2014 to Jan 2015	Removed estimated grant extensions forecasted in Dec and Jun 2014 for a total of \$3,765,720. Reallocated funds outlined below total \$3,893,150. EG-000101 Milestone 1 \$348,852.50 3/2/14 EG-000101 Milestone 2 \$247,037.50 3/15/14 EG-000101 Milestone 3 \$296,445 8/15/14 EG-000101 Milestone 4 \$98,815 3/14/15 EG-011501 Milestone 1 \$316,750 3/2/14 EG-011501 Milestone 2 \$226,250 2/21/14 EG-011501 Milestone 3 \$271,500 6/13/14 EG-011501 Milestone 4 \$90,500 9/26/14 EG-014601 Milestone 1 \$700,000 3/2/14 EG-014601 Milestone 2 \$500,000 4/15/14 EG-014601 Milestone 3 \$600,000 10/14/14 EG-014601 Milestone 4 \$200,000 4/15/15 2015 grant budget reduced by \$127,430 due to grant extensions exceeding budgeted amount for 2014. Estimated 2015 grant payments reduced by amounts below. 2014 Cycle Milestone 1 in May 2014 (\$44,600) 2014 Cycle Milestone 2 in Sep 2014 (\$31,858) 2014 Cycle Milestone 3 in Jan 2015 (\$38,229) 2014 Cycle Milestone 4 in Oct 2015 (\$12,743)	Line 35					
ACCME	REMS Service Fees	Jan to Dec 2014	No invoices received in Jan. Reallocated total amount from Jan-Dec to Feb-Dec @ \$14,454 per month.	Line 39					
TBD	Independent Audit by 3rd Party of CE	Jan to Dec 2014	Audit not expected to happen in 1st half, reallocated total amount (\$130,000) from Jan-Dec to Jul-Dec, 2014 @ \$21,666 per month	Line 40					
TBD	Assessment 3B	Apr to Dec 2014, Jan to Dec 2015	We will not likely have a vendor under contract until Q3 2014. We currently have \$420k distributed evenly from April – December 2014 and \$320k distributed evenly throughout the entire 2015 year. Revised so that \$300k is distributed evenly from September – December 2014; added the remaining \$120k from 2014 to the \$300k currently allocated to 2015 and distributed the \$420k evenly throughout the entire 2015 year.	Line 42					
HealthCore	Assessment 4	Jan 2014 to May 2015	Updated milestone payments based on recently executed contract with vendor. April 2014 - \$146,780; May 2014 - \$188,405; June 2014 - \$68,480; July 2014 - \$27,250; January 2015 - \$22,584; March 2015 - \$110,284; April 2015 - \$10,892; May 2015 - \$66,192.; January 2016 - \$22,584; March 2016 - \$110,284; April 2016 - \$10,892; May 2016 - \$66,192	Line 43					

REMS Changes to Forecast in Summary by Vendor Tab

February 28, 2015

Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	Net Effect - Fav (Unfav)			
						2014	2015	2016	2017
TBD	Assessment 5 (Objectives 1, 5, 6)	Jan to Dec 2014, 2015 and 2016	Objectives 1, 5, and 6 were split into individual lines. Total budget of \$800k was allocated between individual lines. Forecast reallocations are listed below: Objective 1 2014: Evenly distributed \$150,000 across October – December. 2015: Evenly distributed \$300,000 between January and July. 2016: Evenly distributed \$300,000 between January and July. Objective 5 2014: Evenly distributed \$150,000 across October – December. 2015: Evenly distributed \$300,000 between January and July. 2016: Evenly distributed \$300,000 between January and July. Objective 6 2014: March - \$10,000; May - \$15,000. 2015: Evenly distributed \$100,000 between January and July. 2016: Evenly distributed \$100,000 between January and July.	Line 44, 45 and 46					
RMPDC	Assessment 5 (Objectives 2, 3)	Jan to Jul 2014	Reallocated amounts scheduled from Jan-Jul to Mar-Jul to reflect contracting timing	Line 47					
Inflexion	Assessment 5 (Objective 4)	Jan/Feb 2014	Moved \$100,000 expected to be billed in Jan to Feb	Line 48					
IMS	Assessment 6, 7 and 8	Jan to Jul 2014	Assessments 6, 7 and 8 are combined into one line as the tasks have been rolled into one study performed by a single vendor. Overall fees from 2014 plus 2015 are now expected to be \$612k and fall according to milestones. Allocations have been revised such that a milestone payment of \$306k falls in March 2014, a milestone payment of \$153k falls in July 2014, and a milestone payment of \$153k falls in July 2015. Allocations for 2016 have been revised such that one milestone payment falls in July 2016 for \$185,000.	Line 49					
IMS	Assessment 7	Jan to Jul 2014	Assessments 6, 7 and 8 are combined into one line as the tasks have been rolled into one study performed by a single vendor.	N/A					
IMS	Assessment 8	Jan to Jul 2014	Assessments 6, 7 and 8 are combined into one line as the tasks have been rolled into one study performed by a single vendor.	N/A					
Constantine Cannon	Legal	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED					
TBD	Audit Vendor	Jan to Dec 2014	Reallocated amounts scheduled from Jan-Dec to Apr-Dec (\$50,000 per month) to reflect delay in vendor selection to allow evaluation of additional candidate	Line 63					
Polaris	Grant Management System	Mar to Apr 2014	Invoice not received, expected to bill with March invoices	Line 26					
Cenveo	Printing PCDs	Mar 2014	Invoices not previously received for November to January added in March	Line 31					
TBD	PCD translation to Spanish	Mar to Apr 2014	Moved \$25k from March to April as we are waiting for information from the FDA before work can start.	Line 32					
TBD	CE Face to Face Meeting	Mar 2014	Reduced amount from \$12k to \$8k for actual expenses incurred.	Line 33					
Polaris	CE Grants	Mar and May 2014	Moved \$296,445 from March to May for updated schedule for 2012 Grant Extensions	Line 35					
TBD	Admin for RFPs and grant metric reporting	Feb to Mar 2014	Moved \$20,000 from February to March for invoice not received.	Line 37					
ACCME	REMS Service Fees	Feb to Dec 2014	No invoices received in February. Reallocated total amount evenly between April to December at \$15,899 per month.	Line 39					
TBD	Assessment 5 - Objectives 6 (Other surveillance objectives); NSDUH and MTF publically accessible reports	Mar to June 2014, 2015 and 2016	Revised to \$5,550 in June for 2014, 2015 and 2016 based on draft Change Order.	Line 46					
RMPDC	Assessment 5 - Objectives 2 and 3 (RADARS system): Pre/Post REMS Analysis: Active Drug Substance (e.g. ER morphine versus IR morphine, etc.)	Mar to Dec 2014	Revised fee schedule to match draft SOW.	Line 47					

REMS Changes to Forecast in Summary by Vendor Tab

February 28, 2015

Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	Net Effect - Fav (Unfav)			
						2014	2015	2016	2017
Inflexxion	Assessment 5 - Objective 4 (Inflexxion NAVIPPRO)	Feb to Mar 2014	Moved \$100k from February to March for invoice not received.	Line 48					
IMS	Assessment 6, 7 and 8	Mar and May 2014	Moved \$306k from March to May based on estimated SOW execution and schedule of invoicing.	Line 49					
Constantine Cannon	Legal	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED					
Ashfield	Call Center	Mar-Apr 2014	Moved \$3,215 March Fee to April for invoice not received	Line 25					
Polaris	Grant Management System	Mar-Apr 2014	Moved \$19,007.43 March Fee to April for invoice not received	Line 26					
Cenveo	Printing PCDs	Mar-Apr 2014	Moved \$774 March Fee to April for invoice not received	Line 31					
TBD	PCD translation to Spanish	Apr-May 2014	Moved \$25,000 April fee to May	Line 32					
Polaris	CE Grants	Mar-Apr 2014	Moved \$511,273 billing of two grants to April due to payment report not being received in time to bill on March 15.	Line 35					
TBD	Admin for RFPs and grant metric reporting	Mar 2014	Removed \$20,000 from March and \$30,000 from April forecast for funding not utilized.	Line 37					
ACCME	REMS Service Fees	Mar-Dec 2014	Reallocated total amount evenly from April to December for no invoices received. Revised fee will be \$17,666 per month.	Line 39					
RMPDC	Assessment 5-Objectives 2 and 3	Apr-May 2014	Moved \$79,008 to May as first milestone date will be after April 15.	Line 47					
Inflexxion	Assessment 5-Objective 4	2014-2016	Reallocated milestone payments based on executed SOW. Total cost in each year is \$160,000 higher than budgeted.	Line 48					
IMS	Assessment 6, 7 and 8	2014-2015	Reallocated milestone payments based on executed SOW.	Line 49					
UBC	Umbrella Metrics Vendor	Mar-Apr 2014	Moved \$42,190 to April for invoice not received	Line 51					
TBD	Annual Audit Vendor	Apr-Dec 2014	Reallocated total amount evenly from May to December. Revised fee will be \$56,250 per month.	Line 61					
Ashfield	Call Center	Apr, 2014	Actual costs for April were \$22k higher than forecasted	Line 25					
McKesson	Web Communications	Apr, 2014	Change order for website updates billed in April increasing cost by \$7,525.	Line 27					
ACCME	REMS Service Fees	Apr, 2014	Estimated costs \$210k higher than forecasted	Line 39					
Inflexxion	Assessment 5 (Objective 4)	Apr-Jun, 2014	Per contract terms, June costs billed in April for an increase in April of \$200k and a reduction in June of \$200k	Line 48					
UBC	Umbrella Metrics Vendor	Apr, 2014	Actual invoice received \$24,145, forecasted cost was \$66,537 for a reduction of \$42,392	Line 50					
Ashfield	Call Center	May to Jun, 2014	Moved \$12k to June for invoice not received.	Line 25					
McKesson	Web Communications	May to Jun, 2014	Reduced May to \$0 for invoice not received. Increased June to \$12,100 for invoice received.	Line 27					
TBD	PCD Translation to Spanish	May to Jun, 2014	Moved \$25K from May to June to allow for PCD translation if needed. Costs will continue to be pushed on a monthly basis until RPC is able to evaluate if PCD changes and accompanying translation will be needed	Line 32					
TBD	Admin for RFPs and grant metric reporting	June to Dec, 2014	Budget for this line item potentially not needed in 2014 or only at end of 2014, so reforecast full \$45k from June to December	Line 37					
HealthCore	Assessment 4	May to Jun, 2014	Moved \$188,405 from May to June for invoice not received.	Line 43					
UBC	Assessment 5, Objective 6	June, 2015	Removed \$5,550 due to 2014 payment covering 2015.	Line 46					
RMPDC	Assessment 5, Objective 2 and 3	2015 and 2016	Aligned monthly amounts to SOW schedule. Reduced 2015 by \$147k, reduced 2016 by \$111k.	Line 47					
RMPDC	Assessment 5 - Objectives 2 and 3 (RADARS system): Pre/Post REMS Analysis: Active Drug Substance (e.g. ER morphine versus IR morphine, etc.)	May to Jun, 2014	Moved \$920,008 from May to June for invoice not received.	Line 47					
Inflexxion	Assessment 5, Objective 4	2014, 2015 and 2016	Moved all milestone payments ahead by 1.5 months to account for advanced billing per SOW terms except \$100,000 remains in June, 2014.	Line 48					
IMS	Assessment 6, 7 and 8	May to Jun, 2014	Move \$153,000 from May to June for invoice not received.	Line 49					
UBC	Umbrella Metrics Vendor	May to Dec, 2014	Aligned monthly amounts to SOW schedule. Reduced 2014 by \$65k.	Line 51					
TBD	Additional Analysis	May, 2014	Removed \$30,000 for funds not used.	Line 53					
ClinAudits	Annual Audit Vendor	May to Dec, 2014	Initial billing covers first two months expected invoices. Beginning July, monthly cost of \$56,250 reduced to \$36,616.	Line 61					
TBD	PCD translation to Spanish	Jun to Aug 2014	Moved \$25,000 from June to August for invoice not received	Line 32					

REMS Changes to Forecast in Summary by Vendor Tab

February 28, 2015

Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	Net Effect - Fav (Unfav)			
						2014	2015	2016	2017
N/A	CE Face to Face Meeting	Aug to Nov 2014	Move \$16,000 from August to November for next scheduled F2F meeting.	Line 33		-	-	-	-
TBD	Independent Audit by 3rd Party of CE	Jul to Dec 2014	Move \$21,667 per month from July - August to September - December	Line 40		-	-	-	-
HealthCore	Assessment 4	2014 to 2016	Reallocated milestones for FDA Reports 3 and 4 based on SOW. Original milestones forecasted between 2014 and 2016. Revised milestones forecasted between 2014 and 2015. Added forecast for FDA Report 5 and Milestone 1 for FDA Report 6 for \$232,536. FDA Reports 5 and 6 are forecasted with the same timeline and cost as FDA Report 4 with Milestone payments of \$29,584 in November, 2015 and \$209,952 in 2016. Net change to 2014 is an increase of \$210,989. 2015 and 2016 are neutral.	Line 43		(210,989)	-	-	-
UBC	Assessment 5 - Objective 6 (Other surveillance objectives: NSDUH and MTF publically accessible	Jun to Jul 2014	Moved \$5,550 from June to July for invoice not received	Line 46		-	-	-	-
UBC	Umbrella Metrics Vendor	Jun to Jul 2014	Moved \$42,831 from June to July for invoice not received	Line 51		-	-	-	-
TBD	Additional Analysis	Jun, 2014	Removed \$30,000 for funds not used.	Line 53		30,000	-	-	-
Constantine Cannon	Legal	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED
PDRN	DHCPL 3	Jun to Oct 2014	Increase June by \$40,980 and reduce October by \$40,980 for prebilled postage	Line 60		-	-	-	-
ClinAudits	Annual Audit Vendor	June	Increase June by \$10,159 for invoice received.	Line 61		(10,159)	-	-	-
Ashfield	Call Center	Jul to Aug 2014	Moved \$3,215 from July to August for invoice still in approval process.	Line 25		-	-	-	-
ACCME	REMS Service Fees	Jul to Aug 2014	Moved \$61,500 from July to August for invoice not received.	Line 39		-	-	-	-
UBC	Assessment 5 - Objective 6 (Other surveillance objectives: NSDUH and MTF publically accessible	Jul to Aug 2014	Moved \$5,550 from July to August for invoice not received.	Line 46		-	-	-	-
UBC	Umbrella Metrics Vendor	Jul to Aug 2014	Moved \$63,113 from July to August for invoice not received.	Line 51		-	-	-	-
TBD	Journal Article Publications	Jul to Oct 2014	Reallocated from July - September to August - October for work not yet completed.	Line 52		-	-	-	-
ClinAudits	Annual Audit Vendor	Jul to Aug 2014	Moved \$36,616 from July to August for invoice not received.	Line 61		-	-	-	-
Campbell Alliance	Vendor Expenses	Jul 2014	Actual expenses \$4,966 less than expected for month.	Line 56		4,966.00	-	-	-
Linda Kitlinski	CE Consultant	Sep to Dec 2014	Increase September to December by \$13,750 per month for CE consultant.	Line 62		(55,000.00)	-	-	-
RADARS/Inflexion	Assessment Report Re-analysis	Sep 2014	Increase September by \$1,000,000 for estimated costs associated with additional assessment reports for the FDA	Line 63		(1,000,000.00)	-	-	-
Ashfield	Call Center	Aug 2014	Catch up invoices from prior months	Line 25		(2,398.00)	-	-	-
McKesson	Web Communications	Aug 2014	Actual invoice \$2,667 less than forecasted.	Line 27		2,667.00	-	-	-
Polaris	Grant Management System	Aug to Sep 2014	Moved \$20,297 from August to September for invoice not received	Line 26		-	-	-	-
Conveo	Printing PCDs	Aug 2014	Increase August by \$793 for actual invoice received	Line 31		(739.00)	-	-	-
TBD	PCD translation to Spanish	Aug to Sep 2014	Moved \$25,000 from August to September for invoice not received	Line 32		-	-	-	-
Polaris	Central Database (3rd Party Data Aggregation Vendor)	Aug to Sep 2014	Moved \$2,390 from August to September for invoice not received	Line 30		-	-	-	-
ACCME	REMS Service Fees	Aug to Sep 2014	Moved \$123,000 from August to September for invoice not received	Line 39		-	-	-	-
UBC	Assessment 5 - Objectives 6 (Other surveillance objectives); NSDUH and MTF publically accessible reports	2014 to 2016	Reduce August 2014 from \$5,550 to \$2,775 for actual invoice received. Increase July 2015 by \$2,775 and reduce July 2016 by \$2,775 for updated forecast.	Line 46		2,775.00	(2,775.00)	2,775.00	2,775.00
UBC	Umbrella Metrics Vendor	Aug 2014	Increase August by \$67,402 for actual invoice received. Invoice matches current contract schedule.	Line 51		(70,177.00)	-	-	-
Campbell Alliance	Expenses	Aug 2014	Reduce August by \$11,384 for actual cost	Line 56		11,384.00	-	-	-
TBD	Journal Article Publications	Aug to Nov 2014	Reallocated from \$20,000 per month in August to October to \$20,000 per month in September to November	Line 52		-	-	-	-
ClinAudits	Annual Audit Vendor	Aug to Dec 2014	Reallocate remaining fee between September and December for \$54,924 per month	Line 61		-	-	-	-

REMS Changes to Forecast in Summary by Vendor Tab

February 28, 2015

Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	Net Effect - Fav (Unfav)			
						2014	2015	2016	2017
Inflexxion/RMPDC	Secondary Analysis (RADARS, Inflexxion)	Sep 2014	Reduced September by \$883,000 based on actual estimates for report changes by Inflexxion (\$95,000) and RMPDC (\$22,000)	Line 63		883,000.00	-	-	-
RMPDC	Assessment 5 - Objectives 2 and 3 (RADARS system): Pre/Post REMS Analysis: Active Drug Substance (e.g. ER morphine versus IR morphine, etc.)	Oct to Nov 2014	Move \$20,103 from October to November for updated schedule.	Line 47		-	-	-	-
Inflexxion	Assessment 5 - Objective 4 (Inflexxion NAVIPPRO System)	Sep to Oct 2014	Move \$30,000 from September to October for updated schedule	Line 48		-	-	-	-
Cerveo	Printing PCDs	Sep to Oct 2014	Moved \$625 from September to October for invoice not received	Line 31		-	-	-	-
TransPerfect	PCD translation to Spanish	Sep to Oct 2014	Removed \$25,000 from September, increased October by \$125 for actual cost per contract.	Line 32		24,875.00	-	-	-
Polaris	CE Grants	Sep to Oct 2014	Reallocated 2014 grants based on actual milestone payments in LOAs. Increased 2015 budget by \$1,180,157 for 2014 budget being below expected costs.	Line 35		244,613.00	224,536.00	(472,063.00)	(472,063.00)
ACCME	REMS Service Fees	Sep to Oct 2014	Moved \$184,500 from September to October for invoice not received	Line 39		-	-	-	-
TBD	Assessment 3b (Same as CE (Metrics) Long Term CE	Sep to Dec 2014	Reallocated \$300,000 from Oct - Dec at \$100,000 per month. Reduced Sep to \$0.	Line 42		-	-	-	-
TBD	Journal Article Publications	Sep to Dec 2014	Moved \$20,000 per month from Sep - Nov to Oct - Dec	Line 52		-	-	-	-
ClinAudits	Annual Audit Vendor	Sep to Oct 2014	Moved \$31,351 from September to October for actual invoice received	Line 61		-	-	-	-
Campbell Alliance	Expenses	Sep 2014	Reduced September by \$11,475 for actual expenses	Line 56		11,475.00	-	-	-
Linda Kitlinski	CE Consultant	Sep to Dec 2014	Reallocated \$55,000 from Oct 2014-Mar 2015 at \$9,166.67 per month	Line 62		27,500.00	(27,500.00)	-	-
Inflexxion/RMPDC	Secondary Analysis (RADARS, Inflexxion)	Sep to Oct 2014	Moved \$117,000 from September to October for invoice not received	Line 63		-	-	-	-
Constantine Cannon	Legal	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED
TBD	Assessment 5 - Objectives 1 (Other surveillance objectives); ER visits and deaths in claims database analysis;	Oct to Dec 2014	Reallocated fees to \$75,000 per month in Nov and Dec	Line 44		-	-	-	-
TBD	Assessment 5 - Objectives 5 (Other surveillance objectives); Mortality rates using state medical examiner databases	Oct to Dec 2014	Reallocated fees to \$75,000 per month in Nov and Dec	Line 45		-	-	-	-
Inflexxion	Assessment 5 - Objective 4 (Inflexxion NAVIPPRO System)	Nov to Dec 2014	Reduced Nov and Dec by \$30,000 per month	Line 48		60,000.00	-	-	-
Ogilvy + Mather	Awareness Campaign	Nov to Dec 2014	Added \$414,946 in Nov and Dec for new vendor on Awareness Campaign	Line 64		(414,946.00)	-	-	-
Ashfield	Call Center	Oct to Nov 2014	Moved \$2,076 from Oct to Nov for invoice not received. Costs for the call center have decreased for 2015 and 2016 due to both actual transition from live call center to IVR as well as a more accurate cost estimate based on the executed IVR SOW (prior forecasts were anticipated based on estimates provided by potential IVR vendors which were later negotiated down).	Line 25		-	20,600	19,800	(46,000)
Polaris	Grant Management System	2015 to 2017	Adjust forecast per anticipated GMS updates beyond the Polaris SOW. Potential updates include re-design of the CE Search Page per O&M recommendations and CE Provider interface enhancements to improve user-friendliness. Combined with CE Portal Set up line and reduced 2015 budget to \$65,000 with reduction of all future costs as no additional changes are anticipated at this time.	Line 26		-	(52,768)	5,188	(249,192)
McKesson	Web Communications	Oct 2014 and 2017	Increased Oct 2014 by \$5,773 for Custom Development. Increased 2017 by \$110k as part of the annual budget review.	Line 27		(5,773)	-	-	(110,000)
Polaris	CE Portal Setup	2015 to 2017	Adjust forecast per 2015 annual review	Line 28		-	-	-	-
Polaris	Central Database (3rd Party Data Aggregation Vendor)	2017	Adjust forecast per annual review	Line 30		-	-	-	(50,979)

REMS Changes to Forecast in Summary by Vendor Tab

February 28, 2015

Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	Net Effect - Fav (Unfav)			
						2014	2015	2016	2017
			Moved \$565 from Oct to Nov for invoice not received. Adjust forecast per annual review. The 2016 forecast is \$36,000 less than last year's 2016 forecast due to being able to use this year's REMS modification costs for updated numbers.						
Cenveo	Printing PCDs	Oct to Nov 2014		Line 31		-	-	(6,295)	(14,700)
TransPerfect	PCD Translation to Spanish	2015 to 2017	Adjust forecast per annual review	Line 32		-	(263)	(277)	(291)
TBD	CE Face to Face Meeting	2014	Adjust forecast per annual review	Line 33		-	-	-	(52,000)
Polaris	CE Grants	2017	Adjust forecast per annual review. Reduce 2014 grant cycle to \$8.9M and 2015 grant cycle to \$8.75M.	Line 35		(208)	1,499,075	972,064	(10,000,000)
MedBiquitous	Standardized Metrics	2017	Adjust forecast per annual review	Line 36		-	-	-	(18,000)
TBD	Admin for RFPs and grant metric reporting	2014 to 2016	Remove all forecasted funds as CE subteam has determined task is no longer needed."	Line 37		45,000	20,000	20,000	-
ACCME	REMS Service Fees	Oct to Dec 2014 and 2017	Updated 2014 allocation based on ACCME schedule of activities provided and estimated activity fees from approved grant proposals. Updated 2017 per annual budget review.	Line 39		(298,002)	-	-	(225,000)
TBD	Independent Audit by 3rd Party of CE	Oct to Nov 2014	Moved \$43,334 from Oct to Nov for invoice not received. The CE Subteam does not anticipate the need to have CE audited by an Independent 3rd party, outside of ACCME or other Accrediting Organizations until 2017.	Line 40		130,000	-	-	(130,000)
UBC	Assessment 3a	2017	Adjust forecast per annual review	Line 41		-	-	-	(180,000)
UBC	Assessment 3b (Same as CE Metrics) Long Term CE	2014 to 2017	Aligned fees to those in not-yet executed SOW	Line 42		191,258	(130,324)	(230,324)	(550,324)
HealthCore	Assessment 4	2017	Adjust forecast per annual review	Line 43		-	-	-	(209,952)
HealthCore	Assessment 5 - Objectives 1 (Other surveillance objectives); ER visits and deaths in claims database analysis;	2014 to 2017	Aligned fees to those in not-yet executed SOW	Line 44		150,000	(150,930)	(119,887)	(419,887)
TBD	Assessment 5 - Objectives 5 (Other surveillance objectives); Mortality rates using state medical examiner databases	2017	Adjust forecast per annual review	Line 45		-	-	-	(300,000)
UBC	Assessment 5 - Objectives 6 (Other surveillance objectives); NSDUH and MTF publically accessible reports	2017	Adjust forecast per annual review	Line 46		-	-	-	(2,775)
RMPDC	Assessment 5 - Objectives 2 and 3 (RADARS system): Pre/Post REMS Analysis: Active Drug Substance (e.g. ER morphine versus IR morphine, etc.)	2017	Adjust forecast per annual review	Line 47		-	-	-	(637,524)
Inflexxion	Assessment 5 - Objective 4 (Inflexxion/NAVIPPRO)	2014 to 2017	Adjust forecast per annual review	Line 48		-	-	-	(560,000)
IMS	Assessment 6, 7 and 8	2017	Aligned fees to those in not-yet executed SOW	Line 49		-	(32,000)	-	(185,000)
UBC	Umbrella Metrics Vendor	2015 to 2017	Added fees per amendment to address assessment 5.6	Line 51		-	(2,400)	(2,400)	(97,091)
TBD	Journal Article Publications	Oct to Nov 2014	Moved \$20,000 from Oct to Dec for invoice not received	Line 52		-	-	-	(60,000)
TBD	Additional Analysis	2017	Adjust forecast per annual review	Line 53		-	-	-	(150,000)
Campbell Alliance	Fees	2017	Adjust forecast per annual review	Line 54		-	-	-	(1,918,000)
Campbell Alliance	Expenses	Oct 2014 and 2017	Decreased by \$27,169 for actual expenses. Adjust 2017 forecast per annual review	Line 55		27,169	-	-	(180,000)
Constantine Cannon	Legal	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED: REDACTED: PRIVILEGED: REDACTED: PRIVILEGED: REDACTED: PRIVILEGED					
PDRN	DCHPL 3	Oct to Nov 2014	Moved \$89,020 from Oct to Nov for invoice not received. Adjust forecast per annual review.	Line 60		-	-	-	(130,000)
ClinAudits	Annual Audit Vendor	2014 to 2017	Revised fees in light of Subteam decision for less frequent vendor audits and revised per audit fee estimates based on initial audit fees	Line 61		134,866	215,004	199,092	(265,908)
Linda Kitlinski	CE Consultant	Oct to Dec 2014	Reallocated costs to \$13,750 in Nov, Dec	Line 62		-	-	-	-
Topche	PMO Finance Audit	Dec 2014	Increased December from \$0 to \$30K for full amount of proposal received	Line 65		(30,000)	-	-	-

REMS Changes to Forecast in Summary by Vendor Tab

February 28, 2015

Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	Net Effect - Fav (Unfav)			
						2014	2015	2016	2017
Ogilvy + Mather	Awareness Campaign	2014 to 2017	While the current Ogilvy & Mather SOW only covers the initial costs, a rationale for 2015 costs is that it is a soft number estimate for upfront activity which depends on the results of the discovery phase. A rationale for 2016-2017 costs is that even though the CE/EC/Vendor Subteams determined that is it too early to estimate right now, the maintenance expected is usually 1/3 or less than upfront activity.	Line 65		100,000	(3,346,000)	(1,082,000)	(1,082,000)
McKesson	Web Communications	Nov to Dec 2014	Invoice expected to be received in Dec billed in Nov due to delayed billing in Nov.	Line 27		(5,866.00)	-	-	-
TBD	CE Face to Face Meeting	Nov 2014	Actual expenses \$1661	Line 33		26,339.00	-	-	-
Polaris	CE Grants	Nov to Dec 2014	Milestone Payment of \$273,475 moved to Nov to accommodate 90 days advance billing.	Line 35		-	-	-	-
ACCME	REMS Service Fees	Nov 2014	Actual fees for Nov \$331k	Line 39		(60,000.00)	-	-	-
UBC	Assessment 3a	Nov to Dec 2014	Moved \$7,000 from Nov to Dec for invoice not received.	Line 41		-	-	-	-
UBC	Assessment 3b (Same as CE (Metrics) Long Term CE	Nov to Dec 2014	Moved \$51,402 from Nov to Dec for invoice not received.	Line 42		-	-	-	-
RMPDC	Assessment 5 - Objectives 5 (Other surveillance objectives); Mortality rates using state medical examiner databases	Nov to Dec 2014	Reduced \$75,000 from Nov and Dec due to updated proposal received from vendor.	Line 45		150,000.00	-	-	-
TBD	Journal Article Publications	Nov 2014 to Feb 2015	Reallocated costs to \$20,000 in Dec, Jan and Feb.	Line 52		40,000.00	(40,000.00)	-	-
TBD	Additional Analysis	Nov 2014	Moved \$30,000 from Nov to Dec for invoice not received	Line 53		-	-	-	-
PDRN	DCHPL 3	Nov 2014	Reduced by \$15,200 for actual invoice costs.	Line 60		15,200.00	-	-	-
Linda Kitlinski	CE Consultant	Nov to Mar 2014	Reduced November to 0 as no invoice was received. Revised December to \$15,000 and moved \$12,500 to 2015. Costs in 2015 are divided evenly at \$13k over Jan, Feb and Mar.	Line 62		12,500.00	(12,500.00)	-	-
Ogilvy + Mather	Awareness Campaign	Nov to Dec 2014	Moved \$18,922 from Nov to Dec for invoice not received.	Line 64		-	-	-	-
Campbell Alliance	Expenses	2015 to 2017	Moved \$100k from Operations to Development for F2F meetings	Lines 17 and 56		-	-	-	-
HealthCore	Assessment 5 - Objectives 1 (Other surveillance objectives); ER visits and deaths in claims database analysis;	Dec 2014 to Jan 2015	Moved \$117,246 from Jan to Dec for work expected to be completed in early December	Line 44		(117,246.00)	117,246.00	-	-
RMPDC	Assessment 5 - Objectives 2 and 3 (RADARS system): Pre/Post REMS Analysis: Active Drug Substance (e.g. ER morphine versus IR morphine, etc.)	Dec 2014	Increase Dec by \$12,072.28 for Audit fees". Could you revise to "Increase Dec by \$12,072.28 for fees related to participation in audit conducted by ClinAudits.	Line 47		(12,072.28)	-	-	-
Polaris	Central Database (3rd Party Data Aggregation Vendor)	Dec 14	Actual invoice \$4,253 less than forecast	Line 30		4,253	-	-	-
Polaris	CE Grants	Dec 14	Grant EG-00291 payment moved from Dec to Jan to accommodate 90 days advanced billing	Line 35		115,920	(115,920)	-	-
ACCME	REMS Service Fees	Dec 14 to Dec 15	Dec 2014 actual invoice \$4,000 more than forecast, reduced 2015 to remove monthly cost and allocate \$67,500 in October for 2015 fees at a reduced cost of \$500 per activity.	Line 39		(4,000)	157,500	-	-
UBC	Assessment 3a	Dec 14, Jan 15	\$17k moved to January for invoice not received	Line 41		17,000	(17,000)	-	-
UBC	Assessment 3b (Same as CE (Metrics) Long Term CE Eval)	Dec 14, Jan 15	\$109k moved to January for invoice not received	Line 42		108,743.00	(108,743.00)	-	-
HealthCore	Assessment 5 - Objectives 1 (Other surveillance objectives); ER visits and deaths in claims database analysis;	Dec 14, Jan 15	\$117k moved to January for invoice not received	Line 44		117,246.00	(117,246.00)	-	-
RMPDC	Assessment 5 - Objectives 2 and 3 (RADARS system): Pre/Post REMS Analysis: Active Drug Substance (e.g. ER morphine versus IR morphine, etc.)	Dec 14	December reduced by \$12k as work for this task is fully invoiced in 2014	Line 47		12,072.00	-	-	-
TBD	Journal Article Publications	Dec 14, Mar 15	Reallocated to \$20k per month in Jan-Mar from Dec-Feb.	Line 52		20,000.00	(20,000.00)	-	-
TBD	Additional Analysis	Dec 14, Jan 15	Moved \$57,300 to Jan for invoice not received	Line 53		57,300.00	(57,300.00)	-	-

REMS Changes to Forecast in Summary by Vendor Tab

February 28, 2015

Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	Net Effect - Fav (Unfav)			
						2014	2015	2016	2017
Constantine Cannon	Legal	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED
ClinAudits	Annual audit vendor	Dec 14	Reduced by \$8846 for actual invoice received	Line 61		8,846.00	-	-	-
Linda Kitlinski	CE Consultant	Dec 14	Reduced by \$8269 for actual invoice received	Line 62		8,269.00	-	-	-
Ogilvy & Mather	Awareness Campaign	Dec 14, Jan 15	\$211k moved to January for actual invoice received	Line 64		211,396.00	(211,396.00)	-	-
Topche (sub-contractor of ClinAudits)	PMO Finance Audit	Dec 14, Feb 15	\$30k moved to February for updated schedule	Line 65		30,000.00	(30,000.00)	-	-
Campbell Alliance	Expenses	Dec 14	Reduced Dec by \$10,424 for actual cost	Line 56		10,424.00	-	-	-
TBD	CE Face to Face Mtgs, Admin	Mar 15, Apr 15	Move \$12,000 from March to April for updated schedule	Line 33		-	-	-	-
Ashfield (Alliance)	Call Center	Jan-Feb 2015	Moved \$3700 from Jan to Feb for invoice not received	Line 25	Jan 2015	-	-	-	-
UBC	Assessment 3a	Jan-Feb 2015	Moved \$23000 from Jan to Feb for invoice not received	Line 41	Jan 2015	-	-	-	-
UBC	Assessment 3b (Same as CE (Metrics) Long Term CE Eval)	Jan-Feb 2015	Moved \$147893 from Jan to Feb for invoice not received	Line 42	Jan 2015	-	-	-	-
RMPDC	Assessment 5 - Objectives 5 (Other surveillance objectives); Mortality rates using state medical examiner databases	Jan-Feb 2015	Moved \$42858 from Jan to Feb for invoice not received	Line 47	Jan 2015	-	-	-	-
TBD	Journal Article Publications	Jan-Feb 2015	Reallocated from \$20k per month in Jan-Mar to \$20k per month in Feb-Apr	Line 52	Jan 2015	-	-	-	-
TBD	Additional Analysis	Jan-Feb 2015	Moved \$24150 from Jan to Feb for invoice not received	Line 53	Jan 2015	-	-	-	-
Campbell Alliance	Expenses	Jan-Feb 2015	Reduced by \$6488 for actual cost	Line 56	Jan 2015	-	6,488	-	-
Constantine Cannon	Legal	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED
ClinAudits	Annual audit vendor	Jan-Feb 2015	Moved \$29545 from Jan to Feb for invoice not received	Line 61	Jan 2015	-	-	-	-
Linda Kitlinski	CE Consultant	Jan-Feb 2015	Moved \$11652 from Jan to Feb for invoice not received	Line 62	Jan 2015	-	-	-	-
Ogilvy & Mather	Awareness Campaign	Jan-Feb 2015	Moved \$581896 from Jan to Feb for invoice not received	Line 64	Jan 2015	-	-	-	-
UBC	Grantee Reimbursement	Apr-May 2015	Moved \$48000 from Apr to May for updated schedule	Line 66	Jan 2015	-	-	-	-
RMPDC	Assessment 5 - Objectives 2 and 3 (RADARS system): Pre/Post REMS Analysis: Active Drug Substance (e.g. ER morphine versus IR morphine, etc.)	Feb 2015 to Aug 2017	Reallocated funds based on executed SOW	Line 47	Jan 2015	-	239,598	161,310	142,890
Polaris	Grant Management System/CE Portal Setup	Feb to Mar 2015	Moved \$35,000 from Feb to Mar for updated schedule	Line 26	Jan 2015	-	-	-	-
RMPDC	Assessment 5.4	June 2015, 2016, 2017	Added \$241,868 to June 2015, 2016 and 2017 for assessment 5.4.	Line 67	Jan 2015	-	241,868	241,868	241,868
Ashfield (Alliance)	Call Center	Feb 2015	Decrease by \$1,637 for actual invoice	Line 25	Feb 2015	-	1,637	-	-
McKesson	Web Communications	Feb 2015	Increase by \$11,550 for custom updates	Line 27	Feb 2015	-	(11,550)	-	-
Cenveo	Printing PCDs	Feb-Mar 2015	Move \$1,108 from Feb to Mar for no invoice received	Line 31	Feb 2015	-	-	-	-
Polaris	CE Grants	2015-2016	Move milestone 3 payment for EG-000251 from July to Feb for updated schedule and Milestone 4 from Feb to Mar 2015	Line 35	Feb 2015	-	-	-	-
UBC	Assessment 3a	Feb-Mar 2015	Move \$29,000 from Feb to Mar for no invoice received	Line 41	Feb 2015	-	-	-	-
UBC	Assessment 3b (Same as CE (Metrics) Long Term CE Eval)	Feb-Mar 2015	Move \$196,424 from Feb to Mar for no invoice received	Line 42	Feb 2015	-	-	-	-
RMPDC	Assessment 5 - Objectives 5 (Other surveillance objectives); Mortality rates using state medical examiner databases	Feb-Mar 2015	Move \$85,714 from Feb to Mar for no invoice received	Line 45	Feb 2015	-	-	-	-
RMPDC	Assessment 5 - Objectives 2 and 3 (RADARS system): Pre/Post REMS Analysis: Active Drug Substance (e.g. ER morphine versus IR morphine, etc.)	Feb-Dec 2015	Reallocated according to service order	Line 47	Feb 2015	-	-	-	-
TBD	Journal Article Publications	Feb-May 2015	Shifted from Feb-Apr to Mar-May for no activity	Line 52	Feb 2015	-	-	-	-
TBD	Additional Analysis	Feb-Mar 2015	Moved \$24,150 from Feb to Mar for invoice not received	Line 53	Feb 2015	-	-	-	-
Campbell Alliance	Expenses	Feb 2015	Increase expenses by \$29,998 for F2F costs from December	Line 56	Feb 2015	-	(29,998)	-	-
Constantine Cannon	Legal	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED	REDACTED: PRIVILEGED
ClinAudits	Annual audit vendor	Feb-Mar 2015	Moved \$33,854 from Feb to Mar for invoice not received	Line 61	Feb 2015	-	-	-	-
Linda Kitlinski	CE Consultant	Feb-Mar 2015	Reallocated remaining fee between Mar and Apr @ \$19,159 per month.	Line 62	Feb 2015	-	-	-	-

REMS Changes to Forecast in Summary by Vendor Tab

February 28, 2015

Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	Net Effect - Fav (Unfav)			
						2014	2015	2016	2017
			Reallocated Feb to Apr as Feb - \$0, Mar - \$256,241 and Apr as \$1,137,155. Change is due to (1) invoice not received by cutoff date for and (2) to account for timing of potential forecasted fees when 2015 SOW is finalized.						
Ogilvy & Mather	Awareness Campaign	Feb-Apr 2015		Line 64	Feb 2015		-	-	-
Topche (sub-contractor of ClinAudits)	PMO Finance Audit	Feb 2015	Reduced by \$2,006 for actual invoice	Line 65	Feb 2015		2,006		

REMS Changes to Forecast in Summary by Vendor Tab
February 28, 2015

						Net Effect - Fav (Unfav)			
Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017

REMS Changes to Forecast in Summary by Vendor Tab
February 28, 2015

						Net Effect - Fav (Unfav)			
Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017

REMS Changes to Forecast in Summary by Vendor Tab
February 28, 2015

						Net Effect - Fav (Unfav)			
Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017

REMS Changes to Forecast in Summary by Vendor Tab
February 28, 2015

						Net Effect - Fav (Unfav)			
Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017

REMS Changes to Forecast in Summary by Vendor Tab
February 28, 2015

						Net Effect - Fav (Unfav)			
Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017

REMS Changes to Forecast in Summary by Vendor Tab
February 28, 2015

						Net Effect - Fav (Unfav)			
Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017

REMS Changes to Forecast in Summary by Vendor Tab
February 28, 2015

						Net Effect - Fav (Unfav)			
Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017

REMS Changes to Forecast in Summary by Vendor Tab
February 28, 2015

						Net Effect - Fav (Unfav)			
Vendor	Task	Affected Period	Reason	Location on Summary by Vendor	Change Date	2014	2015	2016	2017

2/28/2015

ACTAVIS / WATSON
 ENDO GENERIC PROD / ENDO LABS
 JANSSEN PHARM
 MALLINCKRODT
 MYLAN
 NOVEN
 PURDUE PHARMA
 RHODES PHARM
 ROXANE
 SANDOZ
 THE PHARMANETWORK
 VISTA
 PFIZER
 IMPAX
 APOTEX
 PAR PHARM
 RANBAXY PHARM
 UPSHER-SMITH
 ZOGENIX
 NESHER

Participant Pool

	Prior Year Allocation %	
	IMS Market Share Estimate**	Adjusted Market Share Estimate
b	6.41%	6.44%
c	3.81%	3.82%
d	1.76%	1.77%
e	22.55%	22.66%
f	16.21%	16.28%
g	0.14%	0.14%
j	24.55%	24.67%
k	10.44%	10.49%
l	8.27%	8.31%
m	0.55%	0.55%
p	0.61%	0.62%
q	0.00%	0.00%
s	0.70%	0.70%
t	0.00%	0.00%
u	1.44%	1.45%
v	2.08%	2.09%
w	0.00%	0.00%
x	0.00%	0.00%
y	0.00%	0.00%
z	0.00%	0.00%
	99.53%	100.00%
z		

RPC Member Deposit Activity

2/28/15

Case: 1:17-md-02804-DAP Doc #: 2313-100 Filed: 08/14/19 33 of 49. PageID #: 369862

RPC Member	Operations Market Share	Funds Received	Deposit Requirement	Deposit Account Activity					
				7/12/2012	9/1/2012	12/1/2012	1/1/2013	4/15/2013	4/1/2014
				2012 Deposit Requirements	Reallocation to Add Impax and Apotex	Reallocation to add Par and Combine Watson/Actavis	Reallocation to add Ranbaxy	2012 IMS Actual Data Deposit Reallocation	2013 IMS Actual Data Deposit Reallocation
Actavis Group, I.f.	0.00%	\$0	\$0	\$243,841	-\$7,253	-\$236,588	\$0	\$0	\$0
Endo Pharmaceuticals Inc.	3.82%	\$176,446	\$176,446	\$471,523	-\$7,253	\$0	-\$2,987	-\$199,225	-\$85,612
Janssen Pharmaceuticals, Inc.	1.77%	\$81,701	\$81,701	\$122,474	-\$7,253	\$0	-\$2,987	-\$18,576	-\$11,957
Mallinckrodt, Inc.	22.66%	\$1,045,316	\$1,045,316	\$1,005,917	-\$7,253	\$0	-\$2,987	\$21,253	\$28,386
Mylan Technologies, Inc.	16.28%	\$751,267	\$751,267	\$726,019	-\$7,253	\$0	-\$2,987	-\$517	\$36,005
Noven Pharmaceuticals, Inc.	0.14%	\$6,649	\$6,649	\$113,065	-\$7,253	\$0	-\$2,987	-\$52,203	-\$43,973
Pfizer, Inc.	0.70%	\$32,445	\$32,445	\$106,950	-\$7,253	\$0	-\$2,987	-\$56,221	-\$8,044
Purdue Pharma, L.P.	24.67%	\$1,138,192	\$1,138,192	\$1,268,409	-\$7,253	\$0	-\$2,987	-\$100,689	-\$19,288
Rhodes Pharmaceuticals L.P.	10.49%	\$484,096	\$484,096	\$401,431	-\$7,253	\$0	-\$2,987	-\$70,764	\$163,669
Roxane Laboratories, Inc.	8.31%	\$383,299	\$383,299	\$503,041	-\$7,253	\$0	-\$2,987	-\$43,549	-\$65,953
Sandoz Inc.	0.55%	\$25,449	\$25,449	\$115,417	-\$7,253	\$0	-\$2,987	-\$46,250	-\$33,478
The PharmaNetwork, LLC	0.62%	\$28,464	\$28,464	\$61,790	-\$7,253	\$0	-\$2,987	-\$51,550	\$28,464
VistaPharm, Inc.	0.00%	\$0	\$0	\$58,497	-\$7,253	\$0	-\$2,987	-\$48,257	\$0
Actavis (Formerly Watson Laboratories, Inc.)	6.44%	\$296,969	\$296,969	\$314,874	-\$7,253	\$185,815	-\$2,987	-\$193,751	\$271
Impax Laboratories, Inc.	0.00%	\$0	\$0	\$0	\$50,773	\$0	-\$2,987	-\$47,787	\$0
Apotex	1.45%	\$66,807	\$66,807	\$0	\$50,773	\$0	-\$2,987	-\$47,787	\$66,807
Par Pharmaceuticals	2.09%	\$96,507	\$96,507	\$0	\$0	\$50,773	-\$2,987	\$63,840	-\$15,119
Ranbaxy	0.00%	\$0	\$0	\$0	\$0	\$0	\$47,787	-\$47,348	-\$439
Upsher-Smith Laboratories	0.00%	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Zogenix	0.00%	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Total Deposit				\$5,513,247	\$0	\$0	\$0	-\$939,380	\$39,742

REQUIRED DEPOSIT	\$8,565,317	\$8,565,317
-------------------------	--------------------	--------------------

VARIANCE	-\$3,951,708	-\$3,951,708
-----------------	---------------------	---------------------

COMMENTS:

CE Grant Summary by Grant

2/28/2015

Grant ID	Grantee	Total Amount	Milestone 1: Executuion of Letter of			Milestone 2: Start of First Activity and			Milestone 3: Mid-term of Grant			Milestone 4: Completion of Last		
			Amount	Due	Paid	Amount	Due	Paid	Amount	Due	Paid	Amount	Due	Paid
EG-000101	Boston U	1,857,500.00	650,125.00	12/18/2012	12/18/2012	464,375.00	3/1/2013	2/27/2013	557,250.00	11/1/2013	11/1/2013	185,750.00	6/1/2014	6/2/2014
EG-000115	American College of Physicians, Inc.	1,434,430.00	502,050.50	1/30/2013	1/30/2013	358,607.50	6/1/2013	5/29/2013	430,329.00	3/1/2014	3/3/2014	143,443.00	4/1/2015	
EG-000146	California Academy of Family Physicians	5,997,640.00	2,099,174.00	1/30/2013	1/30/2013	1,499,410.00	4/1/2013	4/1/2013	1,799,292.00	10/1/2013	10/1/2013	599,764.00	4/30/2014	4/30/2014
EG-000204	Utah Medical Association Foundation	838,899.00	293,614.65	2/14/2013	2/14/2013	209,724.75	10/1/2013	10/1/2013	251,669.70	4/1/2014	4/1/2014	83,889.90	4/1/2015	
EG-000206	Association for Hospital Medical Education	379,800.00	132,930.00	1/30/2013	1/30/2013	94,950.00	8/1/2013	8/1/2013	113,940.00	11/15/2013	11/15/2013	37,980.00	5/1/2014	5/1/2014
EG-000228	University of Washington	799,577.00	279,851.95	12/3/2013	12/4/2013	199,894.25	1/1/2014	1/2/2014	239,873.10	6/16/2014	6/18/2014	79,957.70	12/31/2014	1/2/2015
EG-000239	Temple University	498,755.00	174,564.25	12/3/2013	12/4/2013	124,688.75	1/1/2014	1/2/2014	149,626.50	7/31/2014	8/1/2014	49,763.00	2/2/2015	2/2/2015
EG-000240	Montefiore	1,977,300.00	692,055.00	12/3/2013	12/4/2013	494,325.00	1/4/2014	1/2/2014	593,190.00	4/4/2014	4/1/2014	197,730.00	7/5/2014	7/2/2014
EG-000244	AAPM	599,280.00	209,748.00	12/3/2013	12/4/2013	149,820.00	2/2/2014	2/3/2014	179,784.00	8/2/2014	8/1/2014	59,928.00	2/1/2015	2/2/2015
EG-000248	University of Cincinnati	324,705.00	113,646.75	12/3/2013	12/4/2013	81,176.25	3/1/2014	3/3/2014	97,411.50	9/15/2014	9/15/2014	32,470.50	4/14/2015	
EG-000249	Univ of Nebraska Board of Regents	1,105,290.00	390,000.00	12/3/2013	12/4/2013	400,000.00	3/13/2014	3/14/2014	200,000.00	3/23/2015		115,290.00	3/31/2016	
EG-000251	University of North Texas	420,822.00	147,287.70	12/3/2013	12/4/2013	105,205.50	3/16/2014	3/14/2014	126,246.60	10/5/2015		42,082.20	5/1/2015	
EG-000101 Ext	Boston U	988,150.00	345,852.50	3/21/2014	3/20/2014	247,037.50	4/1/2014	4/1/2014	296,445.00	8/1/2014	8/1/2014	98,815.00	2/28/2015	2/27/2015
EG-000115 Ext	American College of Physicians, Inc.	905,000.00	316,750.00	3/6/2014	3/6/2014	226,250.00	3/15/2014	3/14/2014	271,500.00	5/30/2014	5/29/2014	90,500.00	9/12/2014	9/15/2014
EG-000146 Ext	California Academy of Family Physicians	2,000,000.00	700,000.00	3/6/2014	3/6/2014	500,000.00	4/15/2014	4/15/2014	600,000.00	10/1/2014	10/1/2014	200,000.00	4/15/2015	
EG-000267	Trustees of Boston University	1,093,900.00	382,865.00	10/10/2014	10/23/2014	273,475.00	2/28/2015	2/26/2015	328,170.00	8/28/2015		109,390.00	2/28/2016	
EG-000285	Pri-Med Institute, LLC	1,195,217.00	418,325.95	10/26/2014	10/23/2014	298,804.25	11/22/2014	11/21/2014	358,565.10	4/1/2015		119,521.70	6/19/2015	
EG-000269	University of Washington	785,400.00	274,890.00	10/23/2014	10/23/2014	196,350.00	1/1/2015	1/2/2015	235,620.00	7/1/2015		78,540.00	1/1/2016	
EG-000259	CO*RE	3,655,634.00	1,279,471.90	10/23/2014	10/23/2014	913,908.50	11/1/2014	11/21/2014	1,096,690.20	5/1/2015		365,563.40	1/31/2016	
EG-000260	Florida Medical Association	45,613.00	15,964.55	10/30/2014	10/23/2014	11,403.25	10/25/2014	11/21/2014	13,683.90	4/30/2015		4,561.30	11/30/2015	
EG-000291	Postgraduate Institute for Medicine	1,159,200.00	405,720.00	10/23/2014	10/23/2014	289,800.00	12/6/2014	12/5/2014	347,760.00	2/1/2015	2/1/2015	115,920.00	3/14/2015	
EG-000270	Dannemiller, Inc.	757,730.00	265,205.50	10/26/2014	10/23/2014	189,432.50	12/1/2014	12/5/2014	227,319.00	6/1/2015		75,773.00	12/1/2015	
Total Grants Approved		28,819,842.00												

CE Grant Summary by Month

2/28/2015

Grants are billed to RPC 90 days in advance of when each payment is due. This report represents the date payment will be billed to RPC.

RPC Invoice Status Categories

Actual - Milestone has been billed to RPC

Firm - Milestone is scheduled on an executed LOA

Tentative - Milestone forecasted as part of the annual budget and subject to change

2013 - Budget Approved by RPC

<u>Month</u>	<u>Milestone</u>	<u>Amount</u>	<u>RPC Invoice Status</u>	
January	Additional Milestone 1 for 2012 Grants (2012 total budget increased to \$10.5M from \$10M)	177,894.15	Actual	
January	EG-000101 (2012 Grant Cycle) Milestone 2	464,375.00	Actual	
January	Subtotal	642,269.15	-	642,269.15
February	EG-000115 (2012 Grant Cycle) Milestone 2	358,607.50	Actual	
February	EG-000146 (2012 Grant Cycle) Milestone 2	1,499,410.00	Actual	
February	Subtotal	1,858,017.50	-	1,858,017.50
March	No Activity	-		
March	Subtotal	-	-	
Aggregated Milestone 1 and 2 for 2013 Grants as allocated below:				
EG-000228 Milestone 1 \$279,851.95				
EG-000239 Milestone 1 \$174,564.25				
EG-000240 Milestone 1 \$692,055.00				
EG-000244 Milestone 1 \$209,748.00				
EG-000248 Milestone 1 \$113,646.75				
EG-000249 Milestone 1 \$390,000.00				
EG-000251 Milestone 1 \$147,287.70				
EG-000228 Milestone 2 \$199,894.25				
EG-000239 Milestone 2 \$124,688.75				
EG-000240 Milestone 2 \$494,325.00				
EG-000244 Milestone 2 \$149,820.00				
EG-000248 Milestone 2 \$81,176.25				
EG-000249 Milestone 2 \$267,942.10				
April		3,325,000.00	Actual	
April	Subtotal	3,325,000.00	-	3,325,000.00
May	EG-000206 (2012 Grant Cycle) Milestone 2	94,950.00	Actual	
May	Subtotal	94,950.00	-	94,950.00
June	No Activity	-		
June	Subtotal	-	-	-
July	EG-000204 (2012 Grant Cycle) Milestone 2	209,724.75	Actual	

CE Grant Summary by Month

2/28/2015

July	EG-000146 (2012 Grant Cycle) Milestone 3	1,799,292.00	Actual	
July	Subtotal	2,009,016.75	-	2,009,016.75
August	EG-000206 (2012 Grant Cycle) Milestone 3	113,940.00	Actual	
August	EG-000101 (2012 Grant Cycle) Milestone 3	557,250.00	Actual	
August	Subtotal	671,190.00	-	671,190.00
September	No Activity	-		
September	Subtotal	-	-	
October	No Activity	-		
October	Subtotal	-	-	
November	No Activity	-		
November	Subtotal	-	-	
December	EG-000115 (2012 Grant Cycle) Milestone 3	430,329.00	Actual	
December	Subtotal	430,329.00	-	430,329.00
2013	Total	9,030,772.40	-	9,030,772.40

2014 - Budget Approved by RPC

<u>Month</u>	<u>Milestone</u>	<u>Amount</u>	<u>RPC Invoice Status</u>	
January	EG-000251 (2013 Grant Cycle) Milestone 2	105,205.50	Actual	
January	EG-000249 (2013 Grant Cycle) Milestone 2 <i>total payment due is \$400,000.00, pre-payment billed in April, 2013 will cover \$267,942.10.</i>	132,057.90	Actual	
January	EG-000240 (2013 Grant Cycle) Milestone 3	593,190.00	Actual	
January	EG-000204 (2012 Grant Cycle) Milestone 3	251,669.70	Actual	
January	Subtotal	1,082,123.10	-	1,082,123.10
February	EG-000146 (2012 Grant Cycle) Milestone 4	599,764.00	Actual	
February	EG-000206 (2012 Grant Cycle) Milestone 4	37,980.00	Actual	
February	EG-000101 (2012 Grant Extension Cycle) Milestone 1	345,852.50	Actual	
February	EG-000115 (2012 Grant Extension Cycle) Milestone 1	316,750.00	Actual	
February	EG-000146 (2012 Grant Extension Cycle) Milestone 1	700,000.00	Actual	
February	EG-000101 (2012 Grant Extension Cycle) Milestone 2	247,037.50	Actual	
February	EG-000115 (2012 Grant Extension Cycle) Milestone 2	226,250.00	Actual	
February	EG-000146 (2012 Grant Extension Cycle) Milestone 2	500,000.00	Actual	
February	Subtotal	2,973,634.00	-	2,973,634.00
March	EG-000101 (2012 Grant Cycle) Milestone 4	185,750.00	Actual	
March	Subtotal	185,750.00	-	185,750.00

CE Grant Summary by Month

2/28/2015

April	EG-000228 (2013 Grant Cycle) Milestone 3	239,873.10	Actual	
April	EG-000115 (2012 Grant Extension Cycle) Milestone 3	271,500.00	Actual	
April	EG-000240 (2013 Grant Cycle) Milestone 4	197,730.00	Actual	
April	Subtotal	709,103.10	-	197,730.00
May	EG-000239 (2013 Grant Cycle) Milestone 3	149,491.50	Actual	
May	EG-000101 (2012 Grant Extension Cycle) Milestone 3	296,445.00	Actual	
May	EG-000244 (2013 Grant Cycle) Milestone 3	179,784.00	Actual	
	Aggregated Milestone 1 and 2 for 2014 Grants as allocated below:			
	<i>EG-000267 Milestone 1 \$382,865.00</i>			
	<i>EG-000285 Milestone 1 \$418,325.95</i>			
	<i>EG-000269 Milestone 1 \$274,890.00</i>			
	<i>EG-000259 Milestone 1 \$1,279,471.90</i>			
	<i>EG-000260 Milestone 1 \$15,964.55</i>			
	<i>EG-000291 Milestone 1 \$405,720.00</i>			
	<i>EG-000270 Milestone 1 \$265,205.50</i>			
	<i>EG-000259 Milestone 2 \$413,055.30</i>			
May		3,455,498.20	Actual	
May	Subtotal	4,081,218.70	-	4,081,218.70
June	EG-000115 (2012 Grant Extension Cycle) Milestone 4	90,500.00	Actual	
June	EG-000248 (2013 Grant Cycle) Milestone 3	97,411.50	Actual	
June	Subtotal	187,911.50	-	187,911.50
July	EG-000146 (2012 Grant Extension Cycle) Milestone 3	600,000.00	Actual	
July	Check Processing Fees	372.89	Actual	
July	Subtotal	600,372.89	-	600,372.89
August	No Activity	-		
August	Subtotal	-	-	600,372.89
September	No Activity	-		
September	Subtotal	-	-	-
October	EG-000228 (2013 Grant Cycle) Milestone 4	79,957.73	Firm	
October	EG-000285 (2014 Grant Cycle) Milestone 2	298,804.25	Actual	
October	EG-000269 (2014 Grant Cycle) Milestone 2	196,350.00	Firm	
October	EG-000259 (2014 Grant Cycle) Milestone 2	500,850.20	Actual	
October	EG-000260 (2014 Grant Cycle) Milestone 2	11,403.25	Actual	
October	EG-000291 (2014 Grant Cycle) Milestone 2	289,800.00	Firm	
October	EG-000270 (2014 Grant Cycle) Milestone 2	189,432.50	Firm	
October	EG-000239 (2013 Grant Cycle) Milestone 2	(112.50)	Firm	
October	Subtotal	1,566,485.43	-	1,566,485.43
November	Check Processing Fees	282.78	Firm	
November	EG-000244 (2013 Grant Cycle) Milestone 4	59,928.00	Firm	
November	EG-000267 (2014 Grant Cycle) Milestone 2	273,475.00	Firm	

CE Grant Summary by Month

2/28/2015

November	EG-000239 (2013 Grant Cycle) Milestone 4	49,673.00	Firm	
November	EG-000291 (2014 Grant Cycle) Milestone 3	347,760.00	Firm	
November	Subtotal	731,118.78	-	731,118.78
December	EG-000101 (2012 Grant Extension Cycle) Milestone 4	98,815.00	Firm	
December	EG-000249 (2013 Grant Cycle) Milestone 3	200,000.00	Firm	
December	Subtotal	298,815.00	-	298,815.00
2014	Total	12,416,532.50	-	12,505,532.29

2015 - Budget Approved by RPC

<u>Month</u>	<u>Milestone</u>	<u>Amount</u>	<u>RPC Invoice Status</u>	
January	Check Processing Fees	535.86	Firm	
January	EG-000146 (2012 Grant Extension Cycle) Milestone 4	200,000.00	Firm	
January	EG-000291 (2014 Grant Cycle) Milestone 4	115,920.00	Firm	
January	EG-000248 (2013 Grant Cycle) Milestone 4	32,470.50	Firm	
January	EG-000115 (2012 Grant Cycle) Milestone 4	143,443.00	Firm	
January	EG-000204 (2012 Grant Cycle) Milestone 4	83,889.90	Firm	
January	EG-000285 (2014 Grant Cycle) Milestone 3	358,565.10	Firm	
January	Subtotal	934,824.36	-	934,824.36
February	EG-000259 (2014 Grant Cycle) Milestone 3	1,096,690.20	Firm	
February	Cancellation for ACCME fees	(7,500.00)	Firm	
February	Correction to EG-000239 Milestone 4	0.08	Firm	
February	EG-000260 (2014 Grant Cycle) Milestone 3	13,683.90	Firm	
February	Subtotal	1,102,874.18	-	1,102,874.18
March	EG-000270 (2014 Grant Cycle) Milestone 3	227,319.00	Firm	
March	EG-000251 (2013 Grant Cycle) Milestone 3	126,246.60	Firm	
March	EG-000251 (2013 Grant Cycle) Milestone 4	42,082.20	Firm	
March	EG-000285 (2014 Grant Cycle) Milestone 4	119,521.70	Firm	
March	Subtotal	515,169.50	-	515,169.50
April	EG-000269 (2014 Grant Cycle) Milestone 3	235,620.00	Firm	
April	Subtotal	235,620.00	-	
May	Aggregated Milestone 1 for 2015 Grants	3,062,500.00	Tentative	
May	Subtotal	3,062,500.00	-	3,062,500.00
June	EG-000267 (2014 Grant Cycle) Milestone 3	328,170.00	Firm	
June	Subtotal	328,170.00	-	328,170.00
July	No Activity	-	Firm	
July	Subtotal	-	-	-

CE Grant Summary by Month

2/28/2015

August	No Activity	-		
August	Subtotal	-	-	-
September	EG-000260 (2014 Grant Cycle) Milestone 4	4,561.30	Firm	
September	EG-000270 (2014 Grant Cycle) Milestone 4	75,773.00	Firm	
September	1/3 of Milestone 2 for 2015 Grants	729,166.00	Tentative	
September	Subtotal	809,500.30	-	809,500.30
October	1/3 of Milestone 2 for 2015 Grants	729,166.00	Tentative	
October	EG-000269 (2014 Grant Cycle) Milestone 4	78,540.00	Firm	
October	Subtotal	807,706.00	-	807,706.00
November	1/3 of Milestone 2 for 2015 Grants	729,167.00	Tentative	
November	EG-000259 (2014 Grant Cycle) Milestone 4	365,563.40	Firm	
November	Subtotal	1,094,730.40	-	1,094,730.40
December	EG-000267 (2014 Grant Cycle) Milestone 4	109,390.00	Firm	
December	Subtotal	109,390.00	-	109,390.00
2015	Total	<u>9,000,484.74</u>		<u>8,764,864.74</u>

2016 - Budget Approved by RPC

<u>Month</u>	<u>Milestone</u>	<u>Amount</u>	<u>RPC Invoice Status</u>	
January	1/3 of Milestone 3 for 2015 Grants	875,000.00	Tentative	
January	EG-000249 (2013 Grant Cycle) Milestone 4	115,290.00	Firm	
January	Subtotal	990,290.00	-	990,290.00
February	1/3 of Milestone 3 for 2015 Grants	875,000.00	Tentative	
February	Subtotal	875,000.00	-	875,000.00
March	1/3 of Milestone 3 for 2015 Grants	875,000.00	Tentative	
March	Subtotal	875,000.00	-	875,000.00
April	No Activity	-		
April	Subtotal	-	-	-
May	Aggregated Milestone 1 for 2016 Grants	3,500,000.00	Tentative	
May	Subtotal	3,500,000.00	-	3,500,000.00
June	No Activity	-		
June	Subtotal	-	-	
July	No Activity	-		

CE Grant Summary by Month

2/28/2015

July	Subtotal	-	-	
August	No Activity	-		
August	Subtotal	-	-	
September	1/3 of Milestone 2 for 2016 Grants	833,333.00	Tentative	
September	Subtotal	833,333.00	-	833,333.00
October	1/3 of Milestone 2 for 2016 Grants	833,333.00	Tentative	
October	1/3 of Milestone 4 for 2015 Grants	291,666.00	Tentative	
October	Subtotal	1,124,999.00	-	1,124,999.00
November	1/3 of Milestone 2 for 2016 Grants	833,334.00	Tentative	
November	1/3 of Milestone 4 for 2015 Grants	291,666.00	Tentative	
November	Subtotal	1,125,000.00	-	1,125,000.00
December	1/3 of Milestone 4 for 2015 Grants	291,667.00	Tentative	
December	Subtotal	291,667.00	-	291,667.00
2016	Total	9,615,289.00		9,615,289.00

2017 - Budget Not Yet Approved by RPC

<u>Month</u>	<u>Milestone</u>	<u>Amount</u>	<u>RPC Invoice Status</u>	
January	1/3 of Milestone 3 for 2016 Grants	1,000,000.00	Tentative	
January	Subtotal	1,000,000.00	-	1,000,000.00
February	1/3 of Milestone 3 for 2016 Grants	1,000,000.00	Tentative	
February	Subtotal	1,000,000.00	-	1,000,000.00
March	1/3 of Milestone 3 for 2016 Grants	1,000,000.00	Tentative	
March	Subtotal	1,000,000.00	-	1,000,000.00
April	No Activity	-		
April	Subtotal	-	-	-
May	Aggregated Milestone 1 for 2017 Grants	3,500,000.00	Tentative	
May	Subtotal	3,500,000.00	-	3,500,000.00
June	No Activity	-		
June	Subtotal	-	-	-
July	No Activity	-		
July	Subtotal	-	-	-

CE Grant Summary by Month

2/28/2015

August	No Activity	-		
August	Subtotal	-	-	-
September	1/3 of Milestone 2 for 2017 Grants	833,333.00	Tentative	
September	Subtotal	833,333.00	-	833,333.00
October	1/3 of Milestone 2 for 2017 Grants	833,333.00	Tentative	
October	1/3 of Milestone 4 for 2016 Grants	333,333.00	Tentative	
October	Subtotal	1,166,666.00	-	1,166,666.00
November	1/3 of Milestone 2 for 2017 Grants	833,333.00	Tentative	
November	1/3 of Milestone 4 for 2016 Grants	333,334.00	Tentative	
November	Subtotal	1,166,667.00	-	1,166,667.00
December	1/3 of Milestone 4 for 2016 Grants	333,334.00	Tentative	
December	Subtotal	333,334.00	-	333,334.00
2017	Total	<u>10,000,000.00</u>		<u>10,000,000.00</u>



		Days Past Due				
		Current	1-30 Days	31-60 Days	61-90 Days	91+ Days
Apotex Corp	Total: Endo Pharmaceuticals, Inc.	\$ 36,700	\$ 3,224	\$ -	\$ -	\$ -
Endo Pharmaceuticals, Inc.	Total: Endo Pharmaceuticals, Inc.	\$ -	\$ -	\$ -	\$ -	\$ -
Impax Laboratories, Inc.	Total: Janssen Pharmaceuticals, Inc.	\$ (7,566)	\$ -	\$ -	\$ -	\$ -
Janssen Pharmaceuticals, Inc.	Total: Janssen Pharmaceuticals, Inc.	\$ 21,941	\$ 7,289	\$ -	\$ -	\$ -
Mallinckrodt	Total: Mallinckrodt (Covidien)	\$ 325,072	\$ -	\$ -	\$ -	\$ -
Mylan Inc.	Total: Mylan Inc.	\$ 159,467	\$ -	\$ -	\$ -	\$ -
Nesher	Total: Noven Pharmaceuticals, Inc.	\$ -	\$ -	\$ -	\$ -	\$ -
Noven Pharmaceuticals, Inc.	Total: Noven Pharmaceuticals, Inc.	\$ (6,493)	\$ -	\$ -	\$ -	\$ -
Par Pharmaceuticals	Total: Pfizer, Inc.	\$ 23,117	\$ -	\$ -	\$ -	\$ -
Pfizer, Inc.	Total: Pfizer, Inc.	\$ 2,612	\$ -	\$ -	\$ -	\$ -
Purdue Pharma	Total: Purdue Pharma	\$ 327,161	\$ -	\$ -	\$ -	\$ -
Ranbaxy Pharmaceuticals, Inc.	Total: Rhodes Pharmaceuticals L.P.	\$ (7,566)	\$ -	\$ -	\$ -	\$ -
Rhodes Pharmaceuticals L.P.	Total: Rhodes Pharmaceuticals L.P.	\$ 152,215	\$ -	\$ -	\$ -	\$ -
Roxane Laboratories, Inc.	Total: Roxane Laboratories, Inc.	\$ 77,448	\$ 35,084	\$ -	\$ -	\$ -
Sandoz Inc.	Total: Sandoz Inc.	\$ 14,306	\$ -	\$ -	\$ -	\$ -
The PharmaNetwork, LLC	Total: The PharmaNetwork, LLC	\$ (1,805)	\$ -	\$ -	\$ -	\$ -
Upsher-Smith Laboratories	Total: VistaPharm, Inc.	\$ (2,212)	\$ -	\$ -	\$ -	\$ -
VistaPharm, Inc.	Total: VistaPharm, Inc.	\$ (7,566)	\$ -	\$ -	\$ -	\$ -
Watson	Total: Watson Pharmaceuticals, Inc.	\$ -	\$ -	\$ 10,288	\$ -	\$ -
Zogenix, Inc.	Total: Watson Pharmaceuticals, Inc.	\$ (3,076)	\$ -	\$ -	\$ -	\$ -
RPC Total		1,103,755	45,596	10,288	-	-

INVENTIV HEALTH

		Days Past Due											
		Invoice	Date	Terms	Date	DPD	PO #	Amount	Current	1-30 Days	31-60 Days	61-90 Days	91+ Days
APO100	Apotex Corp												
RPC-001U	REMS Program Management Suppor	3640	12/10/14	45	01/24/15	16		(2,176.14)	-	(2,176.14)	-	-	-
RPC-001U	REMS Program Management Suppor	3678	12/10/14	45	01/24/15	16		2,043.34	-	2,043.34	-	-	-
RPC-001U	REMS Program Management Suppor	3724	12/22/14	45	02/05/15	4		3,356.37	-	3,356.37	-	-	-
RPC-001U	REMS Program Management Suppor	3770	01/13/15	45	02/27/15	-18		4,491.32	4,491.32	-	-	-	-
RPC-001U	REMS Program Management Suppor	3814	01/13/15	45	02/27/15	-18		32,208.23	32,208.23	-	-	-	-
	Total: Apotex Corp	Apotex Corp						39,923.12	36,699.55	3,223.57	0.00	0.00	0.00
END100	Endo Pharmaceuticals, Inc.												
RPC-001C	REMS Program Management Suppor	3712	12/22/14	45	02/05/15	4	10001402	-	-	-	-	-	-
	Total: Endo Pharmaceuticals, Inc.	Endo Pharmaceuticals, Inc.						-	0.00	0.00	0.00	0.00	0.00
IMP001	Impax Laboratories, Inc.												
RPC-001T	REMS Program Management Suppor	3654	12/10/14	45	01/24/15	16	4700001554	(4,490.59)	(4,490.59)	-	-	-	0.00
RPC-001T	REMS Program Management Suppor	3677	12/10/14	45	01/24/15	16	4700001554	(3,075.86)	(3,075.86)	-	-	-	0.00
	Total: Impax Laboratories, Inc.	Impax Laboratories, Inc.						(7,566.45)	(7,566.45)	0.00	0.00	0.00	0.00
JAN300	Janssen Pharmaceuticals, Inc.												
RPC-001D	REMS Program Management Suppor	3664	12/10/14	45	01/24/15	16	993020160	3,184.67	-	3,184.67	-	-	-
RPC-001D	REMS Program Management Suppor	3713	12/22/14	45	02/05/15	4	993020160	4,104.67	-	4,104.67	-	-	-
RPC-001D	REMS Program Management Suppor	3756	01/13/15	45	02/27/15	-18	993020160	2,685.20	2,685.20	-	-	-	-
RPC-001D	REMS Program Management Suppor	3805	01/13/15	45	02/27/15	-18	993020160	19,256.17	19,256.17	-	-	-	-
	Total: Janssen Pharmaceuticals, Inc.	Janssen Pharmaceuticals, Inc.						29,230.71	21,941.37	7,289.34	0.00	0.00	0.00
MAL100	Mallinckrodt												
RPC-001E	REMS Program Management Suppor	3757	01/13/15	45	02/27/15	-18	10426881-000	39,782.52	39,782.52	-	-	-	-
RPC-001E	REMS Program Management Suppor	3806	01/13/15	45	02/27/15	-18	10426881-000	285,289.28	285,289.28	-	-	-	-
	Total: Mallinckrodt	Mallinckrodt						325,071.80	325,071.80	-	-	-	-
MYL100	Mylan Inc.												
RPC-001F	REMS Program Management Suppor	3758	01/13/15	45	02/27/15	-18	4300009571	19,515.65	19,515.65	-	-	-	-
RPC-001F	REMS Program Management Suppor	3807	01/13/15	45	02/27/15	-18	4300009571	139,951.07	139,951.07	-	-	-	-
	Total: Mylan Inc.	Mylan Inc.						159,466.72	159,466.72	-	-	-	-
NES100	Nesher												
RPC-001Z	REMS Program Management Suppor	3642	12/10/14	45	01/24/15	16	57398 OP	-	-	-	-	-	-
RPC-001Z	REMS Program Management Suppor	3683	12/10/14	45	01/24/15	16	57398 OP	-	-	-	-	-	-
	Total: Nesher	Nesher						-	-	-	-	-	-
NOV200	Noven Pharmaceuticals, Inc.												
RPC-001G	REMS Program Management Suppor	3632	12/10/14	45	01/24/15	16	57398 OP	(4,260.24)	(4,260.24)	-	-	-	-
RPC-001G	REMS Program Management Suppor	3667	12/10/14	45	01/24/15	16	57398 OP	(2,566.36)	(2,566.36)	-	-	-	-
RPC-001G	REMS Program Management Suppor	3716	12/22/14	45	02/05/15	4	57398 OP	334.05	334.05	-	-	-	-
	Total: Noven Pharmaceuticals, Inc.	Noven Pharmaceuticals, Inc.						(6,492.55)	(6,492.55)	-	-	-	-
PAR100	Par Pharmaceuticals												

INVENTIV HEALTH

										Days Past Due				
		Invoice	Date	Terms	Date	DPD	PO #	Amount	Current	1-30 Days	31-60 Days	61-90 Days	91+ Days	
RPC-0001V	REMS Program Management Suppor	3771	01/13/15	45	02/27/15	-18		2,829.05	2,829.05	-	-	-	-	
RPC-0001V	REMS Program Management Suppor	3815	01/13/15	45	02/27/15	-18		20,287.74	20,287.74	-	-	-	-	
Total: Noven Pharmaceuticals, Inc.		Par Pharmaceuticals						23,116.79	23,116.79	-	-	-	-	
PFI100		Pfizer, Inc.												
RPC-001S	REMS Program Management Suppor	3768	01/13/15	45	02/27/15	-18	N-3198821	319.67	319.67	-	-	-	-	
RPC-001S	REMS Program Management Suppor	3813	01/13/15	45	02/27/15	-18	N-3198821	2,292.40	2,292.40	-	-	-	-	
Total: Pfizer, Inc.		Pfizer, Inc.						2,612.07	2,612.07	-	-	-	-	
PDP100		Purdue Pharma												
RPC-001J	REMS Program Management Suppor	3761	01/13/15	45	02/27/15	-18	4500067225	40,038.25	40,038.25	-	-	-	-	
RPC-001J	REMS Program Management Suppor	3808	01/13/15	45	02/27/15	-18	4500067225	287,123.21	287,123.21	-	-	-	-	
Total: Purdue Pharma		Purdue Pharma						327,161.46	327,161.46	-	-	-	-	
RPI100		Ranbaxy Pharmaceuticals, Inc.												
RPC-001W	REMS Program Management Suppor	3655	12/10/14	45	01/24/15	16		(4,490.59)	(4,490.59)	-	-	-	-	
RPC-001W	REMS Program Management Suppor	3680	12/10/14	45	01/24/15	16		(3,075.86)	(3,075.86)	-	-	-	-	
Total: Ranbaxy Pharmaceuticals, Inc.		Ranbaxy Pharmaceuticals, Inc.						(7,566.45)	(7,566.45)	-	-	-	-	
RHO100		Rhodes Pharmaceuticals L.P.												
RPC-001K	REMS Program Management Suppor	3762	01/13/15	45	02/27/15	-18	4500067179	18,157.07	18,157.07	-	-	-	-	
RPC-001K	REMS Program Management Suppor	3809	01/13/15	45	02/27/15	-18	4500067179	134,058.37	134,058.37	-	-	-	-	
Total: Rhodes Pharmaceuticals L.P.		Rhodes Pharmaceuticals L.P.						152,215.44	152,215.44	-	-	-	-	
ROX200		Roxane Laboratories, Inc.												
RPC-001L	REMS Program Management Suppor	3635	12/10/14	45	01/24/15	16		8,788.38	-	8,788.38	-	-	-	
RPC-001L	REMS Program Management Suppor	3671	12/10/14	45	01/24/15	16		26,295.18	-	26,295.18	-	-	-	
RPC-001L	REMS Program Management Suppor	3763	01/13/15	45	02/27/15	-18		9,478.12	9,478.12	-	-	-	-	
RPC-001L	REMS Program Management Suppor	3810	01/13/15	45	02/27/15	-18		67,969.68	67,969.68	-	-	-	-	
Total: Roxane Laboratories, Inc.		Roxane Laboratories, Inc.						112,531.36	77,447.80	35,083.56	-	-	-	
SAN400		Sandoz Inc.												
RPC-001M	REMS Program Management Suppor	3636	12/10/14	45	01/24/15	16	7750489038	(3,608.93)	(3,608.93)	-	-	-	-	
RPC-001M	REMS Program Management Suppor	3672	12/10/14	45	01/24/15	16	7750489038	(1,125.77)	(1,125.77)	-	-	-	-	
RPC-001M	REMS Program Management Suppor	3720	12/22/14	45	02/05/15	4	7750489038	1,278.56	1,278.56	-	-	-	-	
RPC-001M	REMS Program Management Suppor	3764	01/13/15	45	02/27/15	-18	7750489038	2,173.73	2,173.73	-	-	-	-	
RPC-001M	REMS Program Management Suppor	3811	01/13/15	45	02/27/15	-18	7750489038	15,588.33	15,588.33	-	-	-	-	
Total: Sandoz Inc.		Sandoz Inc.						14,305.92	14,305.92	-	-	-	-	
PHA400		The PharmaNetwork, LLC												
RPC-001P	REMS Program Management Suppor	3583	11/25/14	45	01/09/15	31		1,164.50	1,164.50	-	-	-	-	
RPC-001P	REMS Program Management Suppor	3637	12/10/14	45	01/24/15	16		(3,504.47)	(3,504.47)	-	-	-	-	
RPC-001P	REMS Program Management Suppor	3673	12/10/14	45	01/24/15	16		(894.72)	(894.72)	-	-	-	-	
RPC-001P	REMS Program Management Suppor	3721	12/22/14	45	02/05/15	4		1,430.05	1,430.05	-	-	-	-	
Total: The PharmaNetwork, LLC		The PharmaNetwork, LLC						(1,804.64)	(1,804.64)	-	-	-	-	
UPS001		Upsher-Smith Laboratories												
RPC-001X	REMS Program Management Suppor	3656	12/10/14	45	01/24/15	16	4500121468	(4,490.59)	(4,490.59)	-	-	-	-	
RPC-001X	REMS Program Management Suppor	3681	12/10/14	45	01/24/15	16	4500121468	(3,075.86)	(3,075.86)	-	-	-	-	

		Days Past Due											
		<u>Invoice</u>	<u>Date</u>	<u>Terms</u>	<u>Date</u>	<u>DPD</u>	<u>PO #</u>	<u>Amount</u>	<u>Current</u>	<u>1-30 Days</u>	<u>31-60 Days</u>	<u>61-90 Days</u>	<u>91+ Days</u>
RPC-001X	REMS Program Management Suppor	3773	01/13/15	45	02/27/15	-18	4500121468	655.32	655.32	-	-	-	-
RPC-001X	REMS Program Management Suppor	3816	01/13/15	45	02/27/15	-18	4500121468	4,699.42	4,699.42	-	-	-	-
Total: Upsher-Smith Laboratories		Upsher-Smith Laboratories						(2,211.71)	(2,211.71)	-	-	-	-
VIS100	VistaPharm, Inc.												
RPC-001Q	REMS Program Management Suppor	3653	12/10/14	45	01/24/15	16	062812JF	(4,490.59)	(4,490.59)	-	-	-	-
RPC-001Q	REMS Program Management Suppor	3674	12/10/14	45	01/24/15	16	062812JF	(3,075.86)	(3,075.86)	-	-	-	-
Total: VistaPharm, Inc.		VistaPharm, Inc.						(7,566.45)	(7,566.45)	-	-	-	-
WAT100	Watson												
RPC-001R	REMS Program Management Suppor	3482	11/06/14	45	12/21/14	50	062812JF	10,288.16	-	-	10,288.16	-	-
Total: Watson		Watson						10,288.16	-	-	10,288.16	-	-
ZOG100	Zogenix, Inc.												
RPC-001Y	REMS Program Management Suppor	3682	12/10/14	45	01/24/15	16		(3,075.86)	(3,075.86)	-	-	-	-
Total: Zogenix, Inc.		Zogenix, Inc.						(3,075.86)	(3,075.86)	-	-	-	-
Grand Total:								1,159,639.44	1,103,754.81	45,596.47	10,288.16	-	-
								100%	95%	4%	1%	0%	0%



A
I INVENTIV HEALTH

Days Past Due

		<u>PM</u>	<u>Invoice</u>	<u>Date</u>	<u>Terms</u>	<u>Due</u>	<u>DPD</u>	<u>Amount</u>	<u>Current</u>	<u>1-30 Days</u>	<u>31-60 Days</u>	<u>61-90 Days</u>	<u>91+ Days</u>
ASH250	Ashfield												
RPC-0001	REMS Program Management Support		20246031	12/11/14	75	02/24/15	-15	2,808.09	2,808.09	-	-	-	-
Total: Ashfield								2,808.09	2,808.09	-	-	-	-
CEN001	Cenveo												
RPC-0001	REMS Program Management Support		23443920	11/26/14	75	02/09/15	0	619.13	619.13	-	-	-	-
RPC-0001	REMS Program Management Support		23509241	12/30/14	75	03/15/15	-34	581.22	581.22	-	-	-	-
Total: Cenveo								1,200.35	1,200.35	-	-	-	-
CLI100	ClinAudits												
RPC-0001	REMS Program Management Support		6858	01/12/15	30	02/11/15	-2	12,580.86	12,580.86	-	-	-	-
Total: ClinAudits								12,580.86	12,580.86	-	-	-	-
CON001	Constantine Cannon												
RPC-0001	REMS Program Management Support		44615	01/08/15	75	03/24/15	-43	15,000.00	15,000.00	-	-	-	-
RPC-0001	REMS Program Management Support		44655	01/08/15	75	03/24/15	-43	15,000.00	15,000.00	-	-	-	-
RPC-0001	REMS Program Management Support		44688	01/13/15	75	03/29/15	-48	15,000.00	15,000.00	-	-	-	-
Total: Constantine Cannon								45,000.00	45,000.00	-	-	-	-
HEA100	HealthCore												
RPC-0001	REMS Program Management Support		3214	12/19/14	75	03/04/15	-23	117,246.00	117,246.00	-	-	-	-



A
I INVENTIV HEALTH

Days Past Due

		<u>PM</u>	<u>Invoice</u>	<u>Date</u>	<u>Terms</u>	<u>Due</u>	<u>DPD</u>	<u>Amount</u>	<u>Current</u>	<u>1-30 Days</u>	<u>31-60 Days</u>	<u>61-90 Days</u>	<u>91+ Days</u>
Total: HealthCore								117,246.00	117,246.00	-	-	-	-
IMS100	IMS												
RPC-0001	REMS Program Management Suppor		407211828	12/26/14	75	03/11/15	-30	33,150.00	33,150.00	-	-	-	-
Total: IMS								33,150.00	33,150.00	-	-	-	-
INF100	Inflexxion												
RPC-0001	REMS Program Management Suppor		4716	09/24/14	75	12/08/14	63	-	-	-	-	-	-
Total: Inflexxion								-	-	-	-	-	-
KIT100	Linda Kitlinski												
RPC-0001	REMS Program Management Suppor		LK001	12/16/14	75	03/01/15	-20	230.29	230.29	-	-	-	-
RPC-0001	REMS Program Management Suppor		LK002	12/16/14	75	03/01/15	-20	6,500.54	6,500.54	-	-	-	-
RPC-0001	REMS Program Management Suppor		LK003	01/06/15	75	03/22/15	-41	1,680.75	1,680.75	-	-	-	-
Total: Linda Kitlinski								8,411.58	8,411.58	-	-	-	-
MCK100	McKesson Specialty Arizona, Inc.												
RPC-0001	REMS Program Management Suppor		308407113	12/18/14	75	03/03/15	-22	10,350.00	10,350.00	-	-	-	-
RPC-0001	REMS Program Management Suppor		308530262	01/27/15	75	04/12/15	-62	12,800.00	12,800.00	-	-	-	-
Total: McKesson Specialty Arizona, Inc.								23,150.00	23,150.00	-	-	-	-
MED100	MedBiquitous Consortium, LLC												



A
I INVENTIV HEALTH

Days Past Due

		<u>PM</u>	<u>Invoice</u>	<u>Date</u>	<u>Terms</u>	<u>Due</u>	<u>DPD</u>	<u>Amount</u>	<u>Current</u>	<u>1-30 Days</u>	<u>31-60 Days</u>	<u>61-90 Days</u>	<u>91+ Days</u>
RPC-0001	REMS Program Management Suppor		682	07/11/14	75	09/24/14	138	-	-	-	-	-	-
Total: MedBiquitous Consortium, LLC								-	-	-	-	-	-
OGI100		Ogilvy & Mather											
RPC-0001	REMS Program Management Suppor		30012284	11/18/14	75	02/01/15	8	-	-	-	-	-	-
RPC-0001	REMS Program Management Suppor		30012273	11/24/14	75	02/07/15	2	-	-	-	-	-	-
RPC-0001	REMS Program Management Suppor		30012334	12/01/14	75	02/14/15	-5	-	-	-	-	-	-
Total: Ogilvy & Mather								-	-	-	-	-	-
PDR001		PDR Network, LLC											
RPC-0001	REMS Program Management Suppor		M100427	10/31/14	75	01/14/15	26	-	-	-	-	-	-
Total: PDR Network, LLC								-	-	-	-	-	-
PL001		Polaris Solutions, LLC											
RPC-0001	REMS Program Management Suppor		14382	12/02/14	75	02/15/15	-6	2,461.29	2,461.29	-	-	-	-
RPC-0001	REMS Program Management Suppor		14383	12/02/14	75	02/15/15	-6	19,577.80	19,577.80	-	-	-	-
RPC-0001	REMS Program Management Suppor		14446	01/02/15	75	03/18/15	-37	535.86	535.86	-	-	-	-
RPC-0001	REMS Program Management Suppor		14447	01/02/15	75	03/18/15	-37	2,461.29	2,461.29	-	-	-	-
RPC-0001	REMS Program Management Suppor		14448	01/02/15	75	03/18/15	-37	19,577.80	19,577.80	-	-	-	-
Total: Polaris Solutions, LLC								44,614.04	44,614.04	-	-	-	-
RMP001		RMPDC											

CampbellAlliance®

INVENTIV HEALTH

Days Past Due

		<u>PM</u>	<u>Invoice</u>	<u>Date</u>	<u>Terms</u>	<u>Due</u>	<u>DPD</u>	<u>Amount</u>	<u>Current</u>	<u>1-30 Days</u>	<u>31-60 Days</u>	<u>61-90 Days</u>	<u>91+ Days</u>
RPC-0001	REMS Program Management Suppor		RD00000303	11/19/14	75	02/02/15	7	-	-	-	-	-	-
Total: RMPDC								-	-	-	-	-	-
UBC001	UBC Late Stage, Inc.												
RPC-0001	REMS Program Management Suppor		71003662	07/31/14	75	10/14/14	-41,926	-	-	-	-	-	-
Total: UBC Late Stage, Inc.								-	-	-	-	-	-
Grand Total:								279,749.34	279,749.34	-	-	-	-
Percent of Total:								100%	100.0%	0.0%	0.0%	0.0%	0.0%